WHO methods and data sources for country-level causes of death 2000-2019

Department of Data and Analytics (DNA)
Division of Data, Analytics and Delivery for Impact (DDI)
WHO, Geneva

December 2020
Acknowledgments

This Technical Report was updated by Bochen Cao, Gretchen A. Stevens, Jessica Ho and Doris Ma Fat of the Monitoring, Forecasting and Inequality Unit in the WHO Department of Data and Analytics, in the Division of Data, Analytics and Delivery for Impact of the World Health Organization (WHO), Geneva. Estimates of country-level deaths by cause for years 2000-2019 were led by Bochen Cao. Gretchen A. Stevens and Doris Ma Fat were responsible for analysis of death registration data. These estimates benefitted from advice and inputs from other WHO Departments, collaborating United Nations (UN) Agencies, and WHO expert advisory groups and academic collaborators.

Many of the inputs to these estimates result from collaborations with Interagency Groups, expert advisory groups and academic groups. These include the Interagency Group on Child Mortality Estimation (UN-IGME), the UN Population Division, the Maternal and Child Epidemiology Estimation Group (MCEE), the Maternal Mortality Expert and Interagency Group (MMEIG), the International Agency for Research on Cancer, the Institute of Health Metrics and Evaluation (IHME) at the University of Washington, and various experts collaborating in the IHME Global Burden of Disease Study. While it is not possible to name all those who provided advice, assistance or data, both inside and outside WHO, we would particularly like to note the assistance and inputs provided by John Aponte, Kelly Bienhoff, Bob Black, Freddie Bray, Zoe Brillas, Stephanie Burrows, Diana Estevez, Juliana Daher, Jacques Ferlay, Marta Gacic-Dobo, Patrick Gerland, Philippe Glaziou, Lucia Hug, Kacem Iaych, Robert Jakob, Li Liu, Rafael Lozano, Mary Mahy, Colin Mathers, Ann-Beth Moller, William Msamburi, Mohsen Naghavi, Abdisalan Noor, Minal K. Patel and Danzhen You. The World Health Organization funded this work.

Estimates and analysis are available at:

For further information about the estimates and methods, or to obtain computer codes, please contact healthstat@who.int

Recent papers in this series

Contents
1 Introduction ..................................................................................................................................................4
2 Population and all-cause mortality estimates for years 2000-2019 ...............................................................6
3 Analysis categories ......................................................................................................................................6
4 Countries with useable death registration data ..........................................................................................7
5 Causes of death for children under age 5 years ............................................................................................24
6 Causes of death for China 2000-2019 ...........................................................................................................26
7 Causes of death for India 2000-2019 ............................................................................................................27
8 Methods for specific causes with additional information ............................................................................28
9 Other causes of death for countries without useable data ...........................................................................31
10 Uncertainty of estimates ............................................................................................................................34
11 Conclusions ...............................................................................................................................................36
References ......................................................................................................................................................60
Annex Table A  GHE cause categories and ICD-10 codes ..............................................................................62
Annex Table B  Groupings of countries, areas and territories used for global and regional tabulations ..68
Annex Table C  GATHER checklist ................................................................................................................71
Annex Table D  Methods used for estimation of mortality levels and causes of death, by country, 2000-2019 ............................................................................................................................73
Annex Table E  First-level categories for analysis of child causes of death ......................................................80
1 Introduction

Global, regional, and country statistics on population and health indicators are critical for assessing development and health progress and for guiding resource allocation. Specifically, these data are used to monitor progress towards the health-related targets within the Sustainable Development Goals (SDGs) and WHO's 13th General Programme of Work (GPW13), which will require regular reporting on child mortality, maternal mortality and mortality due to non-communicable diseases, suicide, pollution, road traffic injuries, homicide, natural disasters and conflict.

Previous WHO time series estimates of deaths by cause, age and sex for its Member States\(^1\)\(^2\) have now been updated for years 2000-2019 drawing on more recent data as summarized below. This technical paper documents the data sources and methods used for preparation of these country-level Global Health Estimates (GHE2019) for years 2000-2019. Annex Table A lists the cause of death categories and their definitions in terms of the International Classification of Diseases, Tenth Revision (ICD-10).\(^3\) These estimates are available for years 2000, 2005, 2010, 2015 and 2019 for Member States and for selected regional groupings of countries, areas and territories, defined in Annex Table B, at http://www.who.int/healthinfo/global_health_estimates/en/.

One of the six core functions of WHO is monitoring of the health situation, trends and determinants in the world. Over the years it has cooperated closely with other UN partner agencies like UNICEF, UNAIDS, UNFPA and the UN Population Division to collect and compile global health statistics. There are a number of established UN multi-agency expert group mechanisms for cross-cutting topics such as child mortality (the UN-IGME including UNICEF/WHO/UN Population Division/World Bank), and specific diseases such as HIV/AIDS (UNAIDS Reference Group), maternal mortality (MMEIG including WHO/UNICEF/UNFPA/World Bank), tuberculosis (WHO STAG), malaria (Malaria Reference Group and Roll Back Malaria- Malaria Monitoring and Evaluation Reference Group). Additionally, WHO collaborates with a network of academics (MCEE) to estimate child causes of death. This collaboration succeeds the former Child Health Epidemiology Reference Group (CHERG) of WHO and UNICEF.

Estimates of mortality and causes of death were recently released in October 2020 by the Institute of Health Metrics and Evaluation (IHME) as part of the Global Burden of Disease 2019 study (GBD2019).\(^4\) WHO has drawn on the GBD2019 analyses for selected causes for Member States without comprehensive death registration data as described in Section 9 below.

These WHO Global Health Estimates provide a comprehensive and comparable set of cause of death estimates from year 2000 onwards, consistent with and incorporating UN agency, interagency and WHO estimates for population, births, all-cause deaths and specific causes of death, including:

- most recent vital registration (VR) data for all countries submitting VR data to the WHO Mortality Database (WHO MDB), where the VR data meets certain criteria for completeness and quality;
- updated and additional information on levels and trends for child and adult mortality in many countries without good death registration data;
- improvements in methods used for the estimation of causes of child deaths in countries without good death registration data;
- updated assessments of levels and trends for specific causes of death by WHO programs and interagency groups; and
Global Burden of Disease 2019 (GBD2019) study estimates for other causes in countries without useable VR data or other nationally representative sources of information on causes of death.

Because these estimates draw on new data and on the result of the GBD2019 study, and there have been substantial revisions to methods for many causes, these estimates for the years 2000-2019 are not directly comparable with previous WHO estimates for 2000-2016 or earlier versions. These Global Health Estimates represent the best estimates of WHO, based on the evidence available to it up until November 2020, rather than the official estimates of Member States, and have not necessarily been endorsed by Member States. They have been computed using standard categories, definitions and methods to ensure cross-national comparability and may not be the same as official national estimates produced using alternate, potentially equally rigorous methods. The following sections of this document provide explanatory notes on data sources and methods for preparing mortality estimates by cause.

These estimates have been documented following the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).

Figure 1.1 provides an overview of the overall process of preparing the GHE2019 estimates from the input data sources. Input data and processes are described in more detail in the following Sections.

Figure 1.1 Overview of the processes involved in the preparation of the GHE2019 dataset for causes of death in 183 WHO Member States for years 2000-2019. Refer also to Figure 4.1 for a more detailed summary of the processes involved in the use of death registration data submitted to the WHO Mortality Database and to Figure 9.1 for a summary of the data and processes involved in the preparation of the GHE “prior” estimates dataset.
2  Population and all-cause mortality estimates for years 2000-2019

WHO life tables have been revised and updated for Member States for years 2000-2019, drawing on estimates of deaths and population from the recently released UN World Population Prospects 2019 revision (WPP2019), recent UNAIDS/WHO analyses of HIV mortality for countries with high HIV prevalence, vital registration data, UN-IGME estimates of levels and trends for child mortality under 15 years, as well as all-cause mortality estimates for adults from GBD2019.

Annex Table D summarizes the methods used for preparing life tables. Data sources are documented in more detail in GHE Technical Paper 2020.1. The WHO life tables are available in the Global Health Observatory at http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en

Total deaths by age and sex were estimated for each country by applying the WHO life table death rates to the estimated de facto resident populations prepared by the UN Population Division in its 2019 revision. They may thus differ slightly from official national estimates for corresponding years.

3  Analysis categories

3.1 Countries

Estimates are made for 183 WHO Member States with populations greater than 90,000 in 2019. The 11 Member States excluded are: Andorra, Cook Islands, Dominica, Marshall Islands, Monaco, Nauru, Niue, Palau, Saint Kitts and Nevis, San Marino, and Tuvalu. Additionally, estimates are made for the following territories: Puerto Rico; Taiwan, China; West Bank and Gaza Strip. These are not released individually, but are included in the relevant regional and global totals.

3.2 Age groups

The analysis of deaths by cause is carried out for 5-year age groups from 5-9, through to the final open-ended age group 85+. Deaths under age 5 are estimated for the following age groups: neonatal (0-29 days), post-neonatal (1-11 months), and 1-4 years. Cause of death estimates are released in tabular form for age groups 0-28 days, 1-59 months, 5-14 years, 15-29, 30-49, 50-59, 60-69, 70+ years.

3.3 Cause of death categories

The cause of death categories remain the same as those used in the previous WHO cause of death estimates. The cause list is given in Annex Table A, together with corresponding ICD-10 codes.
4 Countries with useable death registration data

4.1 Data and estimates

Cause-of-death statistics are reported to WHO on an annual basis by country, year, cause, age and sex. These statistics can be accessed in the WHO Mortality Database. For these estimates, a total of 67 countries or territories had data that met our inclusion criteria, of which 33 countries had data for years 2018 or later. Twelve countries had reported data from 2019.

For countries with a high-quality vital registration system including information on cause of death, we used the vital registration data recorded in the WHO Mortality Database to estimate cause-specific deaths. We analyzed the data using the following steps:

1) application of inclusion criteria to select countries with high-quality vital registration data;
2) extraction of deaths by cause group, with a short cause list and, if possible, a detailed cause list (depending on the detail of the data in the WHO Mortality Database);
3) redistribution of deaths of unknown sex/age and deaths assigned to ill-defined (garbage) codes;
4) interpolation/extrapolation of number of deaths for missing country-years;
5) adjustments to take into account additional information for specific causes of death; and
6) scaling of total deaths by age and sex to previously estimated WHO all-cause envelopes for years 2000-2019.

Figure 4.1 provides an overview of the steps involved in preparing the complete dataset for GHE causes and categories for years 2000 to 2019 for the countries with death registration data reported to the WHO Mortality Database and which meet inclusion criteria. Details are provided below.

4.2 Inclusion criteria for countries with high quality death registration data

We applied the following inclusion criteria to data in the WHO mortality database received as of mid-2020:

- The data are for a country/territory included in this analysis (see Section 3.1);
- The data are available for 5-year age groups to ages 85 and over;
- Data were reported to WHO were coded using ICD-9 or ICD-10 (vs. a prior version of ICD);
- At least five years of data were provided by ICD code (vs. a condensed list);
- Both early (1998-2006) and recent (2013-2019) data were reported to WHO;
- The average prevalence of HIV among adults aged 15 to 49 was 1.5% or lower during 2000-2018; and
- The country/territory’s vital registration data were assessed as medium or high quality, as described below.

The concept of “usability” has been developed by WHO in order to assess the overall quality of death registration data. Usability is defined as the percentage of all deaths which are registered with meaningful cause-of-death information. Usability is calculated as completeness (i.e. the percentage of all deaths in a geographic area that are registered with medical certification of cause of death) multiplied by the proportion of registered deaths that are assigned a meaningful cause of death:

\[
\text{Usability} \% = \text{Completeness} \% \times (1 - \text{Deaths assigned to a garbage code} \%)
\]
Note that the completeness used to calculate usability is based on the deaths registered with cause of death and reported to the WHO Mortality Database. This may differ from estimated completeness of all registered deaths (with or without cause) used in the development of WHO life tables.\(^{10}\) Annex Table D lists estimated completeness for the latest year of data reported to the WHO Mortality Database.

Together with information on reporting status, WHO has used data on usability to categorize national death registration data reported to WHO as very low, low, medium or high quality, as described in Section 10. Briefly, data are considered high quality if the country has reported at least 5 years of data from 2008 or later to WHO, reports the latest year of data by ICD code, and has average usability from 2008-latest ≥ 80%. Data are considered medium quality if the country reports at least 5 years of data from 2008 or later to WHO, reports the latest year of data by ICD code, and has average usability during the period 2008-latest ≥ 60% and < 80%. Data may also be considered medium quality if at least 5 years’ data are reported using a shortlist, and the average usability during the period 2008-latest ≥ 80%.

Some data were excluded despite fulfilling our inclusion criteria: from the Philippines, the years 1998-1999 and 2002 were excluded because the trends in specific causes were implausible. Data from Suriname were excluded because of because of implausible trends implied by the data. Data from Kuwait were excluded due to a high percentage of deaths assigned with unknown age and in ill-defined cause categories not captured above. Data from Uzbekistan, Kyrgyzstan and Guatemala were excluded because the cause of death patterns implied by the data were implausible.

For countries which did not meet the criteria for directly using death registration data to estimate causes of death, we have drawn on updated IHME single-cause analyses from the GBD2019 study, as described in Section 9. Note that the IHME modelling strategies do make use of the available death registration data as well as other sources of information on deaths, covariate regression modelling and also draw on patterns of causes of death for similar countries. The country-specific data and IHME analyses can be viewed on their website.\(^{12}\)
Figure 4.1 Overview of the processes involved in the preparation of the GHE2019 dataset for Member States with death registration data meeting inclusion criteria. Refer also to Figure 1.1 for further steps involved in the inclusion of this dataset in the final GHE2019 estimates.
Table 4.1. Characteristics\(^a\) of country vital registration data and inclusion/exclusion\(^b\)

<table>
<thead>
<tr>
<th>Country</th>
<th>Years of data in the WHO mortality database</th>
<th>Years of data used to compute the GHE</th>
<th>Quality</th>
<th>Completeness (ages 15 and over)</th>
<th>Usability(^c)</th>
<th>Were data used for GHE?</th>
<th>Reason data or data-years were excluded</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albania</td>
<td>1998-2010</td>
<td></td>
<td>low</td>
<td>89%</td>
<td>100%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Andorra</td>
<td>2011-2018</td>
<td></td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>77%</td>
<td>84%</td>
<td>no</td>
</tr>
<tr>
<td>Argentina</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>66%</td>
<td>72%</td>
<td>yes</td>
</tr>
<tr>
<td>Austria</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>84%</td>
<td>90%</td>
<td>yes</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>1998-2004, 2007</td>
<td></td>
<td>very low</td>
<td>80%</td>
<td>83%</td>
<td>44%</td>
<td>44%</td>
<td>no</td>
</tr>
<tr>
<td>Bahamas</td>
<td>1998-2014</td>
<td></td>
<td>medium</td>
<td>89%</td>
<td>90%</td>
<td>71%</td>
<td>81%</td>
<td>no</td>
</tr>
<tr>
<td>Bahrain</td>
<td>1998-2014</td>
<td></td>
<td>low</td>
<td>80%</td>
<td>81%</td>
<td>43%</td>
<td>53%</td>
<td>no</td>
</tr>
<tr>
<td>Barbados</td>
<td>2000-2013</td>
<td>2000-2013</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>70%</td>
<td>84%</td>
<td>yes</td>
</tr>
<tr>
<td>Belarus</td>
<td>1998-2003, 2007-2011, 2013-2014, 2018</td>
<td></td>
<td>high</td>
<td>95%</td>
<td>100%</td>
<td>86%</td>
<td>86%</td>
<td>no</td>
</tr>
<tr>
<td>Belgium</td>
<td>1998-2016</td>
<td>1998-2016</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>81%</td>
<td>85%</td>
<td>yes</td>
</tr>
<tr>
<td>Belize</td>
<td>1998-2016</td>
<td></td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>72%</td>
<td>91%</td>
<td>no</td>
</tr>
<tr>
<td>Bolivia (Plurinational State of)</td>
<td>2000-2003</td>
<td></td>
<td>very low</td>
<td>67%</td>
<td>68%</td>
<td>24%</td>
<td>28%</td>
<td>no</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>2011, 2014, 2016</td>
<td>low</td>
<td>100%</td>
<td>100%</td>
<td>71%</td>
<td>74%</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>73%</td>
<td>84%</td>
<td>yes</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>medium</td>
<td>80%</td>
<td>83%</td>
<td>70%</td>
<td>72%</td>
<td>yes</td>
</tr>
</tbody>
</table>

\(^a\) Quality, Completeness (ages 15 and over), Usability, and Were data used for GHE? are based on the completeness and usability of the data in the WHO mortality database and the data used to compute the GHE.

\(^b\) Notes on data completeness and usability may not be available for all countries.

\(^c\) Usability is calculated based on the completeness of the data for ages 15 and over.
<table>
<thead>
<tr>
<th>Country</th>
<th>Start-End</th>
<th>Start-End</th>
<th>Type</th>
<th>Full</th>
<th>Healthy</th>
<th>65-74</th>
<th>80+</th>
<th>Adj.</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulgaria</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>65%</td>
<td>80%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Cabo Verde</td>
<td>2011-2012</td>
<td>2011-2012</td>
<td>low</td>
<td>100%</td>
<td>100%</td>
<td>69%</td>
<td>71%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Canada</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td>92%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Chile</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>86%</td>
<td>91%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>88%</td>
<td>91%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Costa Rica</td>
<td>1998-2017</td>
<td>1998-2017, 2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>89%</td>
<td>93%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Croatia</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>99%</td>
<td>100%</td>
<td>80%</td>
<td>92%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Cuba</td>
<td>1998-2017</td>
<td>2000-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>89%</td>
<td>93%</td>
<td>yes</td>
<td>Unusable ICD version or shortlist</td>
</tr>
<tr>
<td>Cyprus</td>
<td>1999-2000, 2004-2018</td>
<td>2004-2018</td>
<td>medium</td>
<td>89%</td>
<td>97%</td>
<td>66%</td>
<td>77%</td>
<td>yes</td>
<td>Data not available by 5-year age group</td>
</tr>
<tr>
<td>Czechia</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>83%</td>
<td>89%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>82%</td>
<td>86%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Dominica</td>
<td>1998-2015</td>
<td>1998-2015</td>
<td>medium</td>
<td>82%</td>
<td>94%</td>
<td>55%</td>
<td>79%</td>
<td>no</td>
<td>Member state population less than 90,000</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>1998-2013</td>
<td>1998-2013</td>
<td>low</td>
<td>66%</td>
<td>75%</td>
<td>53%</td>
<td>58%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Ecuador</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>low</td>
<td>72%</td>
<td>100%</td>
<td>54%</td>
<td>69%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Egypt</td>
<td>2000-2019</td>
<td>2000-2019</td>
<td>low</td>
<td>100%</td>
<td>100%</td>
<td>42%</td>
<td>54%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>El Salvador</td>
<td>1998-2015</td>
<td>1998-2015</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>58%</td>
<td>71%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>91%</td>
<td>95%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Fiji</td>
<td>1999, 2001-2009, 2011-2012</td>
<td>2019-2015</td>
<td>low</td>
<td>100%</td>
<td>100%</td>
<td>50%</td>
<td>73%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Finland</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>96%</td>
<td>98%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>1998-2016</td>
<td>1998-2016</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>79%</td>
<td>82%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>83%</td>
<td>86%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>67%</td>
<td>75%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Grenada</td>
<td>2001-2018</td>
<td>2001-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>75%</td>
<td>89%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Guatemala</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>medium</td>
<td>87%</td>
<td>89%</td>
<td>65%</td>
<td>73%</td>
<td>no</td>
<td>Ad-hoc exclusion (see text)</td>
</tr>
<tr>
<td>Country</td>
<td>Years</td>
<td>Scope</td>
<td>Type</td>
<td>Prevalence 1</td>
<td>Prevalence 2</td>
<td>Prevalence 3</td>
<td>Prevalence 4</td>
<td>Trend Assessment</td>
<td>Notes</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>---------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Haiti</td>
<td>1999, 2001-2004</td>
<td>1999, 2001-2004</td>
<td>very low</td>
<td>55%</td>
<td>56%</td>
<td>25%</td>
<td>35%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Honduras</td>
<td>2008-2013</td>
<td>2008-2013</td>
<td>very low</td>
<td>18%</td>
<td>19%</td>
<td>16%</td>
<td>18%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Hungary</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>91%</td>
<td>94%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Iceland</td>
<td>1998-2019</td>
<td>2001-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td>94%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Iran (Islamic Republic of)</td>
<td>2013-2016</td>
<td></td>
<td>medium</td>
<td>82%</td>
<td>82%</td>
<td>67%</td>
<td>70%</td>
<td>no</td>
<td>Insufficient trend data</td>
</tr>
<tr>
<td>Iraq</td>
<td>2008, 2015-2016</td>
<td></td>
<td>low</td>
<td>100%</td>
<td>100%</td>
<td>59%</td>
<td>61%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Ireland</td>
<td>1998-2015</td>
<td>1998-2015</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>92%</td>
<td>93%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>79%</td>
<td>83%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>85%</td>
<td>88%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Jamaica</td>
<td>2000-2006, 2009-2014</td>
<td>2000-2006, 2009-2014</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>70%</td>
<td>90%</td>
<td>no</td>
<td>High HIV</td>
</tr>
<tr>
<td>Japan</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>78%</td>
<td>87%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Jordan</td>
<td>2008-2012, 2015</td>
<td></td>
<td>medium</td>
<td>86%</td>
<td>90%</td>
<td>69%</td>
<td>72%</td>
<td>no</td>
<td>Insufficient trend data</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>1998-2015, 2017</td>
<td></td>
<td>high</td>
<td>91%</td>
<td>95%</td>
<td>80%</td>
<td>83%</td>
<td>no</td>
<td>Fewer than five years by ICD code</td>
</tr>
<tr>
<td>Kiribati</td>
<td>1998-2001</td>
<td></td>
<td>very low</td>
<td>33%</td>
<td>33%</td>
<td>20%</td>
<td>22%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Kuwait</td>
<td>1998-2017</td>
<td></td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>76%</td>
<td>88%</td>
<td>no</td>
<td>Ad-hoc exclusion (see text)</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>1998-2016</td>
<td></td>
<td>high</td>
<td>99%</td>
<td>100%</td>
<td>91%</td>
<td>97%</td>
<td>no</td>
<td>Ad-hoc exclusion (see text)</td>
</tr>
<tr>
<td>Latvia</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>88%</td>
<td>95%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Lebanon</td>
<td>2017-2019</td>
<td></td>
<td>very low</td>
<td>55%</td>
<td>56%</td>
<td>31%</td>
<td>34%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Libya</td>
<td>2016-2017</td>
<td></td>
<td>low</td>
<td>100%</td>
<td>100%</td>
<td>52%</td>
<td>54%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Lithuania</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>94%</td>
<td>97%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Luxembourg</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>78%</td>
<td>84%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Malaysia</td>
<td>2000-2014</td>
<td></td>
<td>medium</td>
<td>50%</td>
<td>51%</td>
<td>32%</td>
<td>40%</td>
<td>no</td>
<td>Low quality</td>
</tr>
<tr>
<td>Malta</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>85%</td>
<td>93%</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Periods</td>
<td>Status</td>
<td>Last Year</td>
<td>Second Last Year</td>
<td>Change 1</td>
<td>Change 2</td>
<td>Yearly Change</td>
<td>Final Change</td>
<td>YES/No</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------</td>
<td>---------</td>
<td>-----------</td>
<td>------------------</td>
<td>----------</td>
<td>----------</td>
<td>---------------</td>
<td>--------------</td>
<td>--------</td>
</tr>
<tr>
<td>Mauritius</td>
<td>1998-2019 1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>77%</td>
<td>90%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>1998-2017 1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>89%</td>
<td>92%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mongolia</td>
<td>2016</td>
<td>low</td>
<td>79%</td>
<td>79%</td>
<td>76%</td>
<td>76%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Montenegro</td>
<td>2000-2009</td>
<td>low</td>
<td>89%</td>
<td>98%</td>
<td>61%</td>
<td>67%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Morocco</td>
<td>2000-2004, 2007-2016</td>
<td>very low</td>
<td>50%</td>
<td>53%</td>
<td>21%</td>
<td>27%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td>1998-2018 1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>82%</td>
<td>84%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td>1998-2017 1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>95%</td>
<td>96%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicaragua</td>
<td>1998-2018 1998-2018</td>
<td>high</td>
<td>95%</td>
<td>100%</td>
<td>81%</td>
<td>89%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>1998-2016 1998-2016</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>84%</td>
<td>87%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oman</td>
<td>2009-2010, 2014, 2016-2017</td>
<td>very low</td>
<td>58%</td>
<td>60%</td>
<td>23%</td>
<td>31%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Panama</td>
<td>1998-2017 1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>81%</td>
<td>86%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraguay</td>
<td>1998-2017 1998-2017</td>
<td>medium</td>
<td>90%</td>
<td>91%</td>
<td>61%</td>
<td>76%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peru</td>
<td>1998-2017</td>
<td>low</td>
<td>71%</td>
<td>80%</td>
<td>54%</td>
<td>61%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Philippines</td>
<td>1998-2003, 2006-2011, 2014</td>
<td>high</td>
<td>97%</td>
<td>100%</td>
<td>78%</td>
<td>85%</td>
<td>yes</td>
<td>Ad-hoc exclusion (see text)</td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>1999-2018 1999-2018</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>68%</td>
<td>72%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>1998-2003, 2007-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>75%</td>
<td>83%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>1998-2017 1999-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>85%</td>
<td>87%</td>
<td>yes</td>
<td>Unusable ICD version or shortlist</td>
<td></td>
</tr>
<tr>
<td>Qatar</td>
<td>2001, 2004-2017</td>
<td>very low</td>
<td>54%</td>
<td>57%</td>
<td>33%</td>
<td>40%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Republic of Korea</td>
<td>1998-2019 1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>76%</td>
<td>85%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Republic of Moldova</td>
<td>1998-2018 1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>93%</td>
<td>98%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romania</td>
<td>1998-2018 1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>82%</td>
<td>88%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Russian Federation</td>
<td>1998-2018</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>no</td>
<td>Fewer than five years by ICD code</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saint Kitts and Nevis</td>
<td>1998-2016</td>
<td>medium</td>
<td>81%</td>
<td>81%</td>
<td>49%</td>
<td>73%</td>
<td>no</td>
<td>Member state population less than 90,000</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Start Year</td>
<td>End Year</td>
<td>Period</td>
<td>Observations</td>
<td>Coverage</td>
<td>Complete</td>
<td>Data Quality</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------</td>
<td>----------</td>
<td>--------</td>
<td>--------------</td>
<td>----------</td>
<td>----------</td>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Saint Vincent and the Grenadines</td>
<td>1998-2017</td>
<td>2000-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>75%</td>
<td>91% yes</td>
<td>Unusable ICD version or shortlist</td>
<td></td>
</tr>
<tr>
<td>San Marino</td>
<td>1998-2002, 2005, 2008-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>62%</td>
<td>88% no</td>
<td>Member state population less than 90,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>2009, 2012</td>
<td></td>
<td>very low</td>
<td>28%</td>
<td>29%</td>
<td>12% 13% no</td>
<td>Low quality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>77%</td>
<td>84% yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seychelles</td>
<td>2001-2015</td>
<td></td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>no</td>
<td>Fewer than five years by ICD code</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singapore</td>
<td>1998-2017, 2019</td>
<td>high</td>
<td>96%</td>
<td>97%</td>
<td>89%</td>
<td>92% yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>1998-2010, 2012-2014</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>86%</td>
<td>93% yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>1998-2019</td>
<td>1998-2019</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>86%</td>
<td>91% yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>2017-2018</td>
<td></td>
<td>very low</td>
<td></td>
<td>no</td>
<td>Low quality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>1998-2015</td>
<td></td>
<td>medium</td>
<td>90%</td>
<td>100%</td>
<td>59% 77% no</td>
<td>High HIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>83%</td>
<td>87% yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>1998-2007, 2009-2014</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>59%</td>
<td>64% yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suriname</td>
<td>1998-2014</td>
<td></td>
<td>medium</td>
<td>88%</td>
<td>89%</td>
<td>63%</td>
<td>74% no</td>
<td>Ad-hoc exclusion (see text)</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>1998-2018</td>
<td>1998-2018</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>85%</td>
<td>88% yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>1998-2017</td>
<td>1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>84%</td>
<td>88% yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syrian Arab Republic</td>
<td>1998-2010</td>
<td></td>
<td>low</td>
<td>81%</td>
<td>90%</td>
<td>53%</td>
<td>53% no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Tajikistan</td>
<td>1998-2005, 2016</td>
<td>low</td>
<td>70%</td>
<td>70%</td>
<td>53%</td>
<td>53% no</td>
<td>Low quality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>1998-2000, 2002-2019</td>
<td>low</td>
<td>91%</td>
<td>100%</td>
<td>34%</td>
<td>65% no</td>
<td>Low quality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Republic of North Macedonia</td>
<td>1998-2013</td>
<td>1998-2013</td>
<td>medium</td>
<td>83%</td>
<td>84%</td>
<td>66%</td>
<td>70% yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td>1998-2012</td>
<td></td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td>92% no</td>
<td>Insufficient trend data</td>
<td></td>
</tr>
<tr>
<td>Tunisia</td>
<td>2009, 2013</td>
<td></td>
<td>low</td>
<td>89%</td>
<td>90%</td>
<td>58%</td>
<td>66% no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Periods</td>
<td>Usability</td>
<td>Completeness</td>
<td>Data Source Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>--------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkey</td>
<td>1998-2002, 2004-2016, 2019</td>
<td>medium</td>
<td>73%</td>
<td>91%</td>
<td>58%</td>
<td>71%</td>
<td>no</td>
<td>Insufficient trend data</td>
<td></td>
</tr>
<tr>
<td>Turkmenistan</td>
<td>1998-2015</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>no</td>
<td>Fewer than five years by ICD code</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ukraine</td>
<td>1998-2012, 2014-2015, 2017-2019</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>no</td>
<td>Fewer than five years by ICD code</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td>2005-2010, 2012, 2016, 2019</td>
<td>very low</td>
<td>57%</td>
<td>58%</td>
<td>22%</td>
<td>22%</td>
<td>no</td>
<td>Low quality</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>1998-2016 1998-2016</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td>93%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>United States of America</td>
<td>1998-2017 1998-2017</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>87%</td>
<td>89%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uruguay</td>
<td>1998-2010, 2012-2019 1998-2010,</td>
<td>medium</td>
<td>100%</td>
<td>100%</td>
<td>76%</td>
<td>80%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venezuela (Bolivarian Republic of)</td>
<td>1998-2014 1998-2014</td>
<td>high</td>
<td>100%</td>
<td>100%</td>
<td>88%</td>
<td>90%</td>
<td>yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a) Characteristics of data sources that are common to all sources are not listed in this table. Specifically, all data sources cover all residents nationally unless otherwise noted, are death registration data based on medical certification of death, and cover all ages and both sexes.

b) Only country/territories included in this analysis are listed here (see Section 3.1).

c) Usability range is shown for data years available by ICD code.

d) Summarized cause list used for some years.

e) Completeness was not computed.
4.3 Mapping to the GHE cause lists and redistribution of unknown age/sex or ill-defined cause of death

Included vital registration data were coded according to ICD9, ICD10, or one of several abbreviated cause lists derived from ICD9 or ICD10. Total deaths by cause, age and sex were mapped to the GHE cause list (Annex Table A). We used the complete cause list in Annex Table A if the data were coded using 3- or 4-digit ICD-10 codes or 4-digit ICD-9 codes. For all included data, we extracted the number of deaths by cause, age and sex, using the broad cause categories listed in Table 4.5 (hereafter “shortlist”). In some cases, counts of deaths were not available for specific causes of death. Several causes of death are not available in death registration data coded using ICD10 at the 3-digit level: hepatitis C (acute infections), lymphatic filariasis, Japanese encephalitis, panic disorder, age-related vision disorders, congenital abdominal wall defect, and congenital oesophageal atresia. Deaths for all of these causes were assumed to be zero in the countries with data coded to ICD10 at the 3-digit level.

Adjustments made to all countries

Deaths of unknown sex were redistributed pro-rata within cause-age groups of known sexes, and then deaths of unknown age were redistributed pro-rata within cause-sex groups of known ages.

Cancers with unspecified site (ICD10 codes C76, C80, C97) were redistributed pro-rata to all sites excluding liver, pancreas, ovary, and lung. Additionally, we redistributed cancer of uterus, part unspecified (C55) pro-rata to cervix uteri (C53) and corpus uteri (C54).

Previously published analyses of heart failure\textsuperscript{13,14} have proposed that these deaths be reassigned mainly to ischemic heart disease (IHD; cause 1130), chronic obstructive pulmonary disease (COPD; cause 1180) in older adults, and to IHD, COPD, cardiomyopathy, myocarditis, and endocarditis (cause 1150) and congenital heart anomalies (cause 1440) in children, adolescents and young adults. These destination causes may be called target causes. Following these analyses, we redistributed heart failure and other ill-defined cardiovascular causes of death to IHD and COPD in adults over age 50 and to the four target causes—IHD, COPD, cardiomyopathy, myocarditis, endocarditis, and congenital heart anomalies in people under age 50. As these conditions have strong age and sex patterns, redistribution fractions were calculated by age and sex. We combined available data from three epidemiologically relevant regions, the traditional high-income countries, Eastern Europe and Central Asia, and other countries with usable death registration data, and calculated fractions for each target disease based on their relative frequency in the data. The redistribution fractions are shown in Tables 4.2-4.5.

Most deaths coded to essential hypertension (I10) are likely to have been caused by ischemic heart disease, stroke or kidney disease. These deaths were redistributed pro-rata to these three target diseases (GHE causes 1130, 1140 and 1270).

The small numbers of deaths coded to depression in some countries were re-assigned to suicide.

The majority of deaths assigned an ICD code for accidental poisoning are assigned ICD codes for poisoning by drugs and alcohol (ICD10 codes X40-X45). Most of these deaths are a result of overdose deaths among individuals with a drug or alcohol use disorder, and therefore should have been assigned the ICD code for the relevant drug use disorders. ICD10 codes associated with alcohol and commonly misused drugs (X41-X42, X44-X45) were assigned to the drug or alcohol use disorder category, while the codes associated with medications that are not commonly misused (X40, X43) were assigned to the poisoning category.
We redistributed deaths coded to symptoms, signs and ill-defined conditions (ICD10 codes R00-R94, R96-R99) pro-rata to all non-injury causes of death, and injuries with undetermined intent (ICD10 codes Y10-Y34) pro-rata to all injury causes of death, following previously published methods.\textsuperscript{15}

**Adjustments made to all countries for which ICD9 data were used**

Chlamydia is not included among the 4-digit ICD-9 codes. To estimate chlamydia deaths when they were not available, the mean fraction of other sexually transmitted disease deaths caused by chlamydia was calculated for each country-sex group for the years it was available (i.e., years coded with ICD10), and applied to all years of data coded using ICD-9 for that country. If there were no deaths coded to other sexually transmitted diseases with ICD10 in a given country, the mean fraction for all other countries was used.

It was not possible to carry out the mapping discussed above for misused prescription medications for data coded using ICD9 (about 5% of country-years in the dataset). This resulted in artificial discontinuities in the estimated number of poisoning and drug use deaths in some countries. To better estimate poisoning, alcohol and drug use deaths, the percentage of drug use and poisoning deaths assigned to poisoning was computed for each country using all data coded using ICD10. This percentage was applied to all years of data coded using ICD9.

**Table 4.2. Redistribution fractions for ill-defined cardiovascular causes of death (ICD10 4-digit codes I472, I490, I46, I50, I514, I515, I516, I519, and I709) for the traditionally high-income countries\textsuperscript{a}**

<table>
<thead>
<tr>
<th>GHE target cause</th>
<th>1130</th>
<th>1150</th>
<th>1180</th>
<th>1440</th>
<th>1130</th>
<th>1150</th>
<th>1180</th>
<th>1440</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1%</td>
<td>6%</td>
<td>1%</td>
<td>93%</td>
<td>0%</td>
<td>6%</td>
<td>1%</td>
<td>93%</td>
</tr>
<tr>
<td>1-4</td>
<td>2%</td>
<td>18%</td>
<td>4%</td>
<td>76%</td>
<td>2%</td>
<td>21%</td>
<td>3%</td>
<td>73%</td>
</tr>
<tr>
<td>5-9</td>
<td>4%</td>
<td>26%</td>
<td>4%</td>
<td>66%</td>
<td>3%</td>
<td>31%</td>
<td>4%</td>
<td>61%</td>
</tr>
<tr>
<td>10-14</td>
<td>6%</td>
<td>34%</td>
<td>4%</td>
<td>56%</td>
<td>5%</td>
<td>33%</td>
<td>4%</td>
<td>58%</td>
</tr>
<tr>
<td>15-19</td>
<td>15%</td>
<td>41%</td>
<td>3%</td>
<td>41%</td>
<td>12%</td>
<td>37%</td>
<td>4%</td>
<td>47%</td>
</tr>
<tr>
<td>20-24</td>
<td>31%</td>
<td>41%</td>
<td>3%</td>
<td>25%</td>
<td>22%</td>
<td>41%</td>
<td>4%</td>
<td>33%</td>
</tr>
<tr>
<td>25-29</td>
<td>47%</td>
<td>35%</td>
<td>3%</td>
<td>15%</td>
<td>34%</td>
<td>38%</td>
<td>4%</td>
<td>24%</td>
</tr>
<tr>
<td>30-39</td>
<td>63%</td>
<td>27%</td>
<td>3%</td>
<td>8%</td>
<td>49%</td>
<td>31%</td>
<td>5%</td>
<td>15%</td>
</tr>
<tr>
<td>35-39</td>
<td>74%</td>
<td>19%</td>
<td>3%</td>
<td>4%</td>
<td>61%</td>
<td>24%</td>
<td>6%</td>
<td>9%</td>
</tr>
<tr>
<td>40-44</td>
<td>81%</td>
<td>14%</td>
<td>4%</td>
<td>2%</td>
<td>69%</td>
<td>17%</td>
<td>10%</td>
<td>5%</td>
</tr>
<tr>
<td>45-49</td>
<td>83%</td>
<td>10%</td>
<td>5%</td>
<td>1%</td>
<td>70%</td>
<td>13%</td>
<td>14%</td>
<td>3%</td>
</tr>
<tr>
<td>50-54</td>
<td>91%</td>
<td>0%</td>
<td>9%</td>
<td>0%</td>
<td>77%</td>
<td>0%</td>
<td>23%</td>
<td>0%</td>
</tr>
<tr>
<td>55-59</td>
<td>87%</td>
<td>0%</td>
<td>13%</td>
<td>0%</td>
<td>72%</td>
<td>0%</td>
<td>28%</td>
<td>0%</td>
</tr>
<tr>
<td>60-64</td>
<td>83%</td>
<td>0%</td>
<td>17%</td>
<td>0%</td>
<td>70%</td>
<td>0%</td>
<td>30%</td>
<td>0%</td>
</tr>
<tr>
<td>65-69</td>
<td>79%</td>
<td>0%</td>
<td>21%</td>
<td>0%</td>
<td>69%</td>
<td>0%</td>
<td>31%</td>
<td>0%</td>
</tr>
<tr>
<td>Age Group</td>
<td>70-74</td>
<td>75-79</td>
<td>80-84</td>
<td>85+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-----</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>75%</td>
<td>74%</td>
<td>73%</td>
<td>76%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>26%</td>
<td>27%</td>
<td>24%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>25%</td>
<td>74%</td>
<td>78%</td>
<td>85%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>70%</td>
<td>0%</td>
<td>22%</td>
<td>15%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>26%</td>
<td>2%</td>
<td>15%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30%</td>
<td>6%</td>
<td>2%</td>
<td>0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0%</td>
<td>0%</td>
<td>2%</td>
<td>0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a) Argentina, Australia, Austria, Belgium, Canada, Chile, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Japan, Luxembourg, Malta, Netherlands, New Zealand, Norway, Portugal, Republic of Korea, Singapore, Spain, Sweden, Switzerland, United Kingdom, United States of America, Uruguay
Table 4.3. Redistribution fractions for ill-defined cardiovascular causes of death (ICD10 4-digit codes I472, I490, I46, I50, I514, I515, I516, I519, and I709) for eastern European and central Asian countries

<table>
<thead>
<tr>
<th>Age</th>
<th>1130</th>
<th>1150</th>
<th>1180</th>
<th>1440</th>
<th>1130</th>
<th>1150</th>
<th>1180</th>
<th>1440</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0%</td>
<td>3%</td>
<td>1%</td>
<td>96%</td>
<td>0%</td>
<td>4%</td>
<td>0%</td>
<td>96%</td>
</tr>
<tr>
<td>1-4</td>
<td>0%</td>
<td>11%</td>
<td>3%</td>
<td>86%</td>
<td>0%</td>
<td>14%</td>
<td>3%</td>
<td>84%</td>
</tr>
<tr>
<td>5-9</td>
<td>1%</td>
<td>21%</td>
<td>4%</td>
<td>74%</td>
<td>1%</td>
<td>26%</td>
<td>4%</td>
<td>70%</td>
</tr>
<tr>
<td>10-14</td>
<td>3%</td>
<td>32%</td>
<td>5%</td>
<td>60%</td>
<td>1%</td>
<td>28%</td>
<td>7%</td>
<td>64%</td>
</tr>
<tr>
<td>15-19</td>
<td>16%</td>
<td>38%</td>
<td>6%</td>
<td>40%</td>
<td>10%</td>
<td>30%</td>
<td>6%</td>
<td>54%</td>
</tr>
<tr>
<td>20-24</td>
<td>39%</td>
<td>36%</td>
<td>6%</td>
<td>18%</td>
<td>27%</td>
<td>29%</td>
<td>9%</td>
<td>34%</td>
</tr>
<tr>
<td>25-29</td>
<td>52%</td>
<td>33%</td>
<td>5%</td>
<td>10%</td>
<td>43%</td>
<td>30%</td>
<td>7%</td>
<td>20%</td>
</tr>
<tr>
<td>30-39</td>
<td>64%</td>
<td>28%</td>
<td>4%</td>
<td>4%</td>
<td>51%</td>
<td>29%</td>
<td>8%</td>
<td>12%</td>
</tr>
<tr>
<td>35-39</td>
<td>72%</td>
<td>22%</td>
<td>4%</td>
<td>2%</td>
<td>64%</td>
<td>22%</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td>40-44</td>
<td>77%</td>
<td>17%</td>
<td>5%</td>
<td>1%</td>
<td>73%</td>
<td>17%</td>
<td>7%</td>
<td>3%</td>
</tr>
<tr>
<td>45-49</td>
<td>81%</td>
<td>13%</td>
<td>6%</td>
<td>0%</td>
<td>76%</td>
<td>14%</td>
<td>9%</td>
<td>1%</td>
</tr>
<tr>
<td>50-54</td>
<td>92%</td>
<td>0%</td>
<td>8%</td>
<td>0%</td>
<td>88%</td>
<td>0%</td>
<td>12%</td>
<td>0%</td>
</tr>
<tr>
<td>55-59</td>
<td>90%</td>
<td>0%</td>
<td>10%</td>
<td>0%</td>
<td>88%</td>
<td>0%</td>
<td>12%</td>
<td>0%</td>
</tr>
<tr>
<td>60-64</td>
<td>88%</td>
<td>0%</td>
<td>12%</td>
<td>0%</td>
<td>88%</td>
<td>0%</td>
<td>12%</td>
<td>0%</td>
</tr>
<tr>
<td>65-69</td>
<td>86%</td>
<td>0%</td>
<td>14%</td>
<td>0%</td>
<td>90%</td>
<td>0%</td>
<td>10%</td>
<td>0%</td>
</tr>
<tr>
<td>70-74</td>
<td>85%</td>
<td>0%</td>
<td>15%</td>
<td>0%</td>
<td>91%</td>
<td>0%</td>
<td>9%</td>
<td>0%</td>
</tr>
<tr>
<td>75-79</td>
<td>85%</td>
<td>0%</td>
<td>15%</td>
<td>0%</td>
<td>92%</td>
<td>0%</td>
<td>8%</td>
<td>0%</td>
</tr>
<tr>
<td>80-84</td>
<td>86%</td>
<td>0%</td>
<td>14%</td>
<td>0%</td>
<td>93%</td>
<td>0%</td>
<td>7%</td>
<td>0%</td>
</tr>
<tr>
<td>85+</td>
<td>89%</td>
<td>0%</td>
<td>11%</td>
<td>0%</td>
<td>95%</td>
<td>0%</td>
<td>5%</td>
<td>0%</td>
</tr>
</tbody>
</table>

a) Armenia, Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Republic of Moldova, Romania, Serbia, Slovakia, Slovenia, Republic of North Macedonia
Table 4.4. Redistribution fractions for ill-defined cardiovascular causes of death (ICD10 4-digit codes I472, I490, I46, I50, I514, I515, I516, I519, and I709) for all other countries

<table>
<thead>
<tr>
<th>GHE target cause</th>
<th>1130</th>
<th>1150</th>
<th>1180</th>
<th>1440</th>
<th>1130</th>
<th>1150</th>
<th>1180</th>
<th>1440</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Redistribution fractions for males</td>
<td>Redistribution fractions for females</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0%</td>
<td>3%</td>
<td>1%</td>
<td>96%</td>
<td>0%</td>
<td>3%</td>
<td>1%</td>
<td>96%</td>
</tr>
<tr>
<td>1-4</td>
<td>1%</td>
<td>9%</td>
<td>4%</td>
<td>85%</td>
<td>1%</td>
<td>10%</td>
<td>3%</td>
<td>86%</td>
</tr>
<tr>
<td>5-9</td>
<td>4%</td>
<td>15%</td>
<td>5%</td>
<td>77%</td>
<td>3%</td>
<td>15%</td>
<td>4%</td>
<td>78%</td>
</tr>
<tr>
<td>10-14</td>
<td>8%</td>
<td>23%</td>
<td>5%</td>
<td>63%</td>
<td>7%</td>
<td>22%</td>
<td>5%</td>
<td>67%</td>
</tr>
<tr>
<td>15-19</td>
<td>39%</td>
<td>24%</td>
<td>6%</td>
<td>32%</td>
<td>30%</td>
<td>23%</td>
<td>6%</td>
<td>42%</td>
</tr>
<tr>
<td>20-24</td>
<td>59%</td>
<td>21%</td>
<td>5%</td>
<td>15%</td>
<td>44%</td>
<td>23%</td>
<td>6%</td>
<td>26%</td>
</tr>
<tr>
<td>25-29</td>
<td>69%</td>
<td>19%</td>
<td>5%</td>
<td>8%</td>
<td>53%</td>
<td>23%</td>
<td>7%</td>
<td>17%</td>
</tr>
<tr>
<td>30-39</td>
<td>75%</td>
<td>16%</td>
<td>5%</td>
<td>4%</td>
<td>65%</td>
<td>19%</td>
<td>7%</td>
<td>9%</td>
</tr>
<tr>
<td>35-39</td>
<td>79%</td>
<td>14%</td>
<td>5%</td>
<td>2%</td>
<td>72%</td>
<td>16%</td>
<td>7%</td>
<td>5%</td>
</tr>
<tr>
<td>40-44</td>
<td>82%</td>
<td>12%</td>
<td>6%</td>
<td>1%</td>
<td>77%</td>
<td>12%</td>
<td>9%</td>
<td>2%</td>
</tr>
<tr>
<td>45-49</td>
<td>83%</td>
<td>9%</td>
<td>7%</td>
<td>1%</td>
<td>78%</td>
<td>10%</td>
<td>11%</td>
<td>1%</td>
</tr>
<tr>
<td>50-54</td>
<td>90%</td>
<td>0%</td>
<td>10%</td>
<td>0%</td>
<td>85%</td>
<td>0%</td>
<td>15%</td>
<td>0%</td>
</tr>
<tr>
<td>55-59</td>
<td>86%</td>
<td>0%</td>
<td>14%</td>
<td>0%</td>
<td>82%</td>
<td>0%</td>
<td>18%</td>
<td>0%</td>
</tr>
<tr>
<td>60-64</td>
<td>82%</td>
<td>0%</td>
<td>18%</td>
<td>0%</td>
<td>79%</td>
<td>0%</td>
<td>21%</td>
<td>0%</td>
</tr>
<tr>
<td>65-69</td>
<td>77%</td>
<td>0%</td>
<td>23%</td>
<td>0%</td>
<td>77%</td>
<td>0%</td>
<td>23%</td>
<td>0%</td>
</tr>
<tr>
<td>70-74</td>
<td>72%</td>
<td>0%</td>
<td>28%</td>
<td>0%</td>
<td>75%</td>
<td>0%</td>
<td>25%</td>
<td>0%</td>
</tr>
<tr>
<td>75-79</td>
<td>68%</td>
<td>0%</td>
<td>32%</td>
<td>0%</td>
<td>74%</td>
<td>0%</td>
<td>26%</td>
<td>0%</td>
</tr>
<tr>
<td>80-84</td>
<td>66%</td>
<td>0%</td>
<td>34%</td>
<td>0%</td>
<td>73%</td>
<td>0%</td>
<td>27%</td>
<td>0%</td>
</tr>
<tr>
<td>85+</td>
<td>66%</td>
<td>0%</td>
<td>34%</td>
<td>0%</td>
<td>74%</td>
<td>0%</td>
<td>26%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Adjustments made to specific countries

An adjustment was made for estimates of deaths due to cancer of the colon and rectum for Australia. In Australia, the term "bowel cancer" is often used as a synonym for large intestine on death certificates. However, as the bowel does not refer to a specific site in the digestive tract, the ICD-10 directs the coding of the term "bowel cancer" to C260. The GHE grouping for colon and rectum cancers is C18-C21. As many codes in C260 are a cancer of the colon or rectum, there will be an under estimate in this GHE grouping, as C26 is included in "other malignant neoplasms". For Australia, deaths coded to C260 were included in the GHE cause category 650 for colon and rectal cancers.
GHE categories 950 “Alzheimer disease and other dementias” and 1010 “Other neurological conditions” contain 74% of the deaths coded to neurological causes in the death registration data available by ICD code. “Other neurological conditions” accounted for a median of 17% of deaths, but in some countries accounted for much higher proportions of deaths. This may be a result of miscertification of dementia deaths to ill-defined neurological causes. To assess this, the ratio of deaths from other neurological conditions (cause 1010) to Alzheimer and other dementias (cause 950) was computed. This ratio had a median value of 0.50, but was much higher in some countries. These high values indicate miscertification of dementia deaths to causes in the other neurological category. In countries that had a ratio over 3 (approximately the 90th percentile), a fraction of deaths in the 1010 cause group were reassigned to alzheimer and other dementias, to obtain a ratio of 1.5 (approximately the 75th percentile). The countries affected and fractions were as follows: El Salvador (36%), Guyana (22%), Nicaragua (21%), Philippines (25%), Singapore (30%), and Sri Lanka (40%).

Similarly, GHE categories 1180 “Chronic obstructive pulmonary disease” (COPD) and 1200 “Other chronic respiratory diseases” contain 96% of the deaths coded to chronic respiratory causes in the death registration data included in GHE, with the remainder assigned to asthma. Other chronic respiratory disease accounted for a median across all countries of 29% of deaths, but in some countries accounted for much higher proportions of deaths, e.g. 79% in Argentina. This may be a result of miscertification of COPD deaths to other chronic respiratory causes. To assess this, the ratio of number of deaths from other chronic respiratory diseases (cause 1200) to COPD (cause 1180) was computed. This ratio had a median value of 0.45, but was much higher in some countries. In countries that had a ratio over 2 (approximately the 90th percentile), a fraction of deaths in the 1200 cause group were reassigned to COPD, to obtain a ratio of 0.80 (approximately the 75th percentile). The countries affected and fractions were as follows: Antigua and Barbuda (42%), Argentina (44%), Barbados (45%), Cyprus (34%), Japan (40%), Mauritius (42%), and St. Vincent and the Grenadines (34%).

In Mauritius, the introduction of ICD10 in 2005 resulted in a shift of deaths from ischemic heart disease and stroke to diabetes, which resulted in a more than tripling the number of diabetes deaths recorded and a simultaneous reduction in the cardiovascular causes. To generate a consistent time-series, the percentage of deaths from these three causes that were assigned to diabetes from 2005-2010 (50.5%) was applied to the years 2004 and prior.

In Greece, a large number of deaths were assigned upper respiratory infection as an underlying cause of death during years coded using ICD-9. The ratio of upper respiratory infection deaths to lower respiratory infection deaths from years coded using ICD-10 was applied to years coded using ICD-9.

### 4.4 Interpolation and extrapolation for missing country-years

For many countries, data were missing for some years. In order to create a continuous time-series of data from 2000 to 2015, we interpolated mortality rates for each country and cause, and then extrapolated at the beginning and end of the data series. Interpolation and extrapolation was carried out separately for the detailed cause list and the short cause list. All shortlist interpolations and extrapolations were carried out using all available data meeting the inclusion criteria. A description of the methods follows.

For each country-age-sex-cause group of the detailed cause list:

1) We interpolated by calculating the mean death rate of all available data in a seven-year window (three years on either side, no earlier than 1998).

2) We extrapolated up to 12 years from the first/last year of data by applying the mean death rate from the first three or last three years of data to the missing data-years.
For each country-age-sex-cause group of the shortlist cause list:

1) We interpolated by fitting a logistic regression for each missing country-age-sex-cause group, using death rates six years prior (but no earlier than 1998) and six years after the missing data year as the dependent variable and year as the independent variable. In some cases, few deaths were recorded for a specific country-age-sex-cause group and the logistic regression did not converge. In that case, the death rate was estimated as the average rate in the three years prior and three years following the missing data year (as was done for the detailed cause list).

2) Extrapolation method depended on mean number of deaths in the first/last three years of data:
   - If there were an average of more than 250 deaths, a logistic regression was fitted to the first or the final six years of data (including interpolated estimates) for each country-sex-cause.
   - If there were an average 250 or fewer deaths, we extrapolated up to six years from the first/last year of data by applying the mean death rate from the first three or last three years of data to the missing data-years (as was done for the detailed cause list).

Because more shortlist data were available than detailed list data, and shortlist data were interpolated and extrapolated using regression methods that reflect trends in death rates, deaths by cause according to the detailed cause list were adjusted to sum to the totals in the filled-in shortlist dataset. This implied no change when the detailed cause list data were available (most country-years).

4.5 Adjustment of specific causes

Estimates for HIV deaths were compared with UNAIDS/WHO estimates. In general, the VR-based estimates were used. For five countries the UNAIDS/WHO estimates were used: El Salvador, Nicaragua, Panama, Saint Lucia, Venezuela. For another five countries, an average of the UNAIDS-based and VR-based deaths was used: Armenia, Barbados, Paraguay, the Republic of Moldova, Sri Lanka.

WHO estimates for maternal deaths include an upwards adjustment for under-recording of maternal deaths in death registration data. Maternal deaths were adjusted using these country-specific factors, and all other causes adjusted pro-rata.

Where necessary, road injury deaths were adjusted upwards to take account of additional surveillance data provided by countries (see Section 8.15). Homicide deaths were similarly adjusted where relevant to take account of homicide data from the police/justice sector (see Section 8.16).

Estimates of deaths due to conflicts (see Section 8.17) were compared with estimates from the death registration data year by year and added “outside-the-envelope” for country-years where they are not included in death registration data.
Table 4.5. Short cause list used for vital registration data coded using ICD-9 or ICD-10 abbreviated cause lists

<table>
<thead>
<tr>
<th>GHE code</th>
<th>Shortlist cause category</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>I. Communicable, maternal, perinatal and nutritional conditions</td>
</tr>
<tr>
<td>20</td>
<td>A. Infectious and parasitic diseases</td>
</tr>
<tr>
<td>30</td>
<td>A1. Tuberculosis</td>
</tr>
<tr>
<td>100</td>
<td>A3. HIV/AIDS</td>
</tr>
<tr>
<td>220</td>
<td>A9a. Malaria</td>
</tr>
<tr>
<td>380</td>
<td>B. Respiratory infections</td>
</tr>
<tr>
<td>390</td>
<td>B1. Lower respiratory infections</td>
</tr>
<tr>
<td>420</td>
<td>C. Maternal conditions</td>
</tr>
<tr>
<td>490</td>
<td>D. Neonatal conditions</td>
</tr>
<tr>
<td>540</td>
<td>E. Nutritional deficiencies</td>
</tr>
<tr>
<td>600</td>
<td>II. Noncommunicable diseases</td>
</tr>
<tr>
<td>610</td>
<td>A. Malignant neoplasms</td>
</tr>
<tr>
<td>620</td>
<td>A1. Mouth and oropharynx cancers</td>
</tr>
<tr>
<td>630</td>
<td>A2. Oesophagus cancer</td>
</tr>
<tr>
<td>640</td>
<td>A3. Stomach cancer</td>
</tr>
<tr>
<td>650</td>
<td>A4. Colon and rectum cancers</td>
</tr>
<tr>
<td>660</td>
<td>A5. Liver cancer</td>
</tr>
<tr>
<td>680</td>
<td>A7. Trachea, bronchus and lung cancers</td>
</tr>
<tr>
<td>700</td>
<td>A9. Breast cancer</td>
</tr>
<tr>
<td>710</td>
<td>A10. Cervix uteri cancer</td>
</tr>
<tr>
<td>740</td>
<td>A13. Prostate cancer</td>
</tr>
<tr>
<td>800</td>
<td>C. Diabetes mellitus</td>
</tr>
<tr>
<td>820</td>
<td>E/F. Mental and neurological disorders</td>
</tr>
<tr>
<td>940</td>
<td></td>
</tr>
<tr>
<td>1100</td>
<td>H. Cardiovascular diseases</td>
</tr>
<tr>
<td>1130</td>
<td>H3. Ischaemic heart disease</td>
</tr>
<tr>
<td>1140</td>
<td>H4. Stroke</td>
</tr>
<tr>
<td>1170</td>
<td>I. Respiratory diseases</td>
</tr>
<tr>
<td>1180</td>
<td>I1. Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>1190</td>
<td>I2. Asthma</td>
</tr>
<tr>
<td>1200</td>
<td>I3. Other respiratory diseases</td>
</tr>
<tr>
<td>1210</td>
<td>J. Digestive disorders</td>
</tr>
<tr>
<td>1230</td>
<td>J2. Liver cirrhosis</td>
</tr>
<tr>
<td>1260</td>
<td>K. Genitourinary diseases</td>
</tr>
<tr>
<td>1400</td>
<td>N. Congenital anomalies</td>
</tr>
<tr>
<td>1510</td>
<td>III. Injuries</td>
</tr>
<tr>
<td>1520</td>
<td>A. Unintentional injuries</td>
</tr>
<tr>
<td>1530</td>
<td>A1. Road injury</td>
</tr>
<tr>
<td>1600</td>
<td>B. Intentional injuries</td>
</tr>
<tr>
<td>1610</td>
<td>B1. Self-harm</td>
</tr>
<tr>
<td>1620</td>
<td>B2. Interpersonal violence</td>
</tr>
<tr>
<td>1630</td>
<td>B3. Collective violence and legal intervention</td>
</tr>
</tbody>
</table>
5 Causes of death for children under age 5 years

5.1 Child deaths

The MCEE-WHO\(^1\) collaboration prepares estimates of deaths for children under age 5 for 15 cause categories using methods described elsewhere by Liu et al.\(^{18}\) and a previously published technical paper\(^{19}\). Previous MCEE-WHO estimates have been updated to years 2000-2017 as described elsewhere\(^{19}\) and already separately released in the WHO Global Health Observatory. For causes for which WHO technical programmes have updated estimates after the release of the MCEE-WHO estimates, those updates were incorporated. For the remaining MCEE-WHO causes without estimates for 2018 and 2019, the estimates were projected forward to 2019 using the Generalized Additive Model for the present GHE update. Additionally, MCEE-WHO estimates for children under age 5 years are not sex-specific and grouped into neonatal (0-28 days) and post-neonatal (1-59 months) that are not disaggregated the same way as GHE, i.e., sex-specific rates for three age categories under age of 5-years, namely 0-28 days, 1-11 months, and 1-4 years. Therefore, sex and age splits were performed using the all-cause mortality envelope based on complete VR data or IGME estimates, population estimates from WPP2019, and age and sex distribution by cause from GBD2019.

The separate methods used by MCEE-WHO for child causes of death for China and India are summarized below in Sections 5.2 and 5.3. Note that the WHO-MCEE cause estimates and the GBD2019 sub-cause distributions are derived from death registration data for those countries with useable death registration data.

The fifteen cause categories used for the WHO-MCEE estimates of under 5 deaths for years 2000-2017 (see Annex Table E) include all the major causes of neonatal (0-27 days) and post-neonatal (1-59 months) and two residual categories containing all remaining causes of death (“Other Group 1” and “Other Group 2”). Cause groups such as “Congenital malformations” and “Injuries” were expanded to the full GHE cause list (Annex Table A) for neonatal and under 5 deaths using sub-cause distributions derived from the GBD2019 estimates.\(^4\)

5.2 Child deaths in China

Estimates of causes of death under age 5 by MCEE-WHO were based on a separate analysis of the China Maternal and Child Surveillance System (MCMSS). Cause-specific estimates of deaths for children under age 5 were estimated for 15 cause categories using data obtained from China Maternal and Child Surveillance System (MCMSS) for years 2000-2016 by age-sex-residency-region strata. The methods used are described in more detail in a technical paper in this series.\(^{18}\)

Total numbers of deaths were estimated based on subnational live births and MCMSS strata-specific mortality rates smoothed using a three-year moving average, and normalized to fit IGME all-cause number of death estimates. Cause-specific death proportions from MCMSS, smoothed using a 7-year

---

\(^{1}\) At the time of the GHE analysis, the latest available MCEE-WHO estimates were for the period 2000-2017. The MCEE-WHO estimates are currently being updated to provide causes of death information for children and adolescents under 19 years of age in 2000-2019. The new analysis employs a new multinomial Bayesian Lasso model with updated national vital registration data, new country-based studies and revisions to single cause of death estimates from a variety of sources. Accordingly, the updated GHE estimates for age under 5 years are expected to be different to some extent from the forthcoming MCEE-WHO estimates, and any similarities or differences between the two sets of estimates should be interpreted with caution.
moving average, were applied to the estimated total number of deaths to obtain the estimated number of deaths by cause by strata prior to summing to obtain national estimates.

5.3 Child deaths in India

In order to estimate trends in under 5 causes of death for India, the previously subnational analyses developed by MCEE-WHO were further refined and used to develop national estimates for years 2000-2017. For neonates, a verbal autopsy multi-cause model (VAMCM) based on 37 sub-national Indian community-based VA studies was used to predict the cause distribution of deaths at state level. The resulting cause-specific proportions were applied to the estimated total number of neonatal deaths to obtain the estimated number of deaths by cause at state level prior to summing to obtain national estimates.

For children who died in the ages of 1-59 months in India, an India-specific multi-cause model (18) was rerun for years 2000-2017 after an updated systematic review was conducted to identify 27 new study data points of sub-national community-based VA studies, plus 22 sets of observations for the Indian states derived from the Million Death Study (20). Nine cause categories were specified, including measles plus the eight specified in the post-neonatal VAMCM for other countries. State-level measles deaths were then normalized to fit the national measles estimates produced by the WHO IVB. State-level AIDS and malaria estimates were provided by UNAIDS and WHO malaria program, respectively. All cause fractions were adjusted to sum to one. The state-level estimates were collapsed to obtain national estimates at the end.
6 Causes of death for China 2000-2019

6.1 Data sources for causes of death

Cause-specific mortality data for China were available from three sources – the sample vital registration (VR) system data for years 1987 to 2012,20 summary deaths tabulations from the Diseases Surveillance Points (DSP) system for years 1995-1998 and 2004-201221,22 and the newly merged and expanded VR and DSP system for 2013-2016, referred to as the Death Registration (DR) system.23 The Death Registration system also includes larger numbers of in-hospital deaths so that the total deaths recorded in the system reached 4 million deaths in 2012.24 The numbers of deaths recorded in the sample representative sites for DSP, VR and DR systems is summarized in Table 6.1 below.

Table 6.1 Total deaths and population covered by the Chinese vital registration system (VR), the Disease Surveillance Points system (DSP) and the newly merged Death Registration system (DR).

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of deaths</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>VR</td>
<td>DSP</td>
</tr>
<tr>
<td>2000</td>
<td>711,946</td>
<td>...</td>
</tr>
<tr>
<td>2001</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>2002</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>2003</td>
<td>626,392</td>
<td>...</td>
</tr>
<tr>
<td>2004</td>
<td>295,906</td>
<td>430,994</td>
</tr>
<tr>
<td>2005</td>
<td>310,826</td>
<td>437,490</td>
</tr>
<tr>
<td>2006</td>
<td>379,057</td>
<td>347,057</td>
</tr>
<tr>
<td>2007</td>
<td>475,289</td>
<td>401,008</td>
</tr>
<tr>
<td>2008</td>
<td>471,219</td>
<td>424,683</td>
</tr>
<tr>
<td>2009</td>
<td>505,021</td>
<td>437,550</td>
</tr>
<tr>
<td>2010</td>
<td>558,915</td>
<td>453,211</td>
</tr>
<tr>
<td>2011</td>
<td>775,458</td>
<td>437,490</td>
</tr>
<tr>
<td>2012</td>
<td>929,249</td>
<td>459,836</td>
</tr>
<tr>
<td>2013</td>
<td>...</td>
<td>...</td>
</tr>
</tbody>
</table>

... data not available.

These sets of data were previously assessed and compared for suitability in estimating GHE2015 cause-specific mortality for China at the national level (GHE Technical Paper WHO/HIS/HSI/GHE/2016.3). The VR and DSP datasets gave quite similar cause distributions at major cause group level by age, across the period 2000-2010. Additionally, comparison for more detailed major causes of death did not give any clear indication that one data set was of systematically higher quality than the other.

With the merger of the two systems in 2013, and the expansion of urban sample sites, the urban-rural composition of the sampled populations changed to be more nationally representative. For earlier years, WHO analyses had re-weighted urban and rural samples from DSP and VR to give approximate national representativeness. However, the DR dataset for 2013-2016 also uses a different set of cause
categories, resulting some inconsistencies with the earlier datasets which were not resolvable given the available cause-specific information. In these cases, data from GBD2019 were used to reconcile such inconsistencies.

6.2 Estimation of deaths by cause for ages 5 and over

For causes for which WHO has specific estimates as described in Section 8 below, these estimates were used. For other causes, cause fractions from the GBD2019 estimates were used, adjusted to the WHO envelope for these causes. The GBD2019 estimates were derived from available Chinese data on causes of death at national and sub-national levels, with major inputs coming from the DSP and VR sample systems for years 2000-2012, with additional data on deaths in Chinese hospitals. For years 2017-2019, the GBD2019 time trends were used to project the estimates for 2000-2016 forward.

7 Causes of death for India 2000-2019

Analysis of causes of death for India in the previous revisions of GHE was based on data from the Sample Registration system (SRS) for limited years covering only the periods 2001-2003 and 2010-2013. These data were derived from representative samples of deaths in the SRS sampling areas, for which verbal autopsy methods were used to assign cause of death. The Sample Registration System monitors a representative sample population of over 6 million people in over 1 million homes in India. In 2013, a total of 7,597 sample units covered a total population of 7.5 million people, of whom 2.0 million were in urban areas and 5.5 million in rural areas.

In 2001 the Indian Registrar General Surveyor introduced an enhanced form of verbal autopsy for assessing the cause of death. Verbal autopsy is a method of ascertaining the cause of death by interviewing a family member or caretaker of the deceased to obtain information on the clinical signs, symptoms and general circumstances that preceded the death. Details of methods and validation have been reported elsewhere. Verbal autopsy reports were independently coded to ICD-10 categories by at least two of a total of 130 physicians trained in ICD-10 coding. In case of disagreement on the ICD-10 codes at the chapter level, reconciliation between reports was conducted, followed by a third senior physician’s adjudication.

A total of 122,848 deaths between January 2001 and December 2003, and a total of 182,827 deaths for 2010-2013 were assigned causes of death by verbal autopsy. Verbal autopsies could not be conducted for around 10% of the deaths for reasons such as family migration or change of residence.

The cause-specific proportion of deaths in each five-year age category from 0 to 79 years and for people aged 80 years and over was weighted by the inverse probability of a household being selected within rural and urban subdivisions of each state to account for the sampling design. National estimates for deaths and mortality rates were based on reweighted urban and rural estimates for India, by age, sex and area.

The analysis in previous GHE revisions was based on the resulting national-level cause-specific mortality proportions derived for GHE cause categories from the SRS data. GBD cause fractions were used to redistribute deaths to detailed sub-cause categories in cases where the SRS cause categories were broader than the GHE cause categories.

For causes for which full time series estimates for years included for the GHE analysis were not available from WHO technical programs and UNAIDS (see Section 8), the trends for the full period were estimated as follows. For example, the GHE2016 analysis made use of the trends estimated by IHME in the GBD2016 study. The GBD2016 estimates for years 2000-2016 were rescaled for consistency with the total deaths across all such causes estimated from WHO life tables and cause-specific estimates. Age-sex-cause specific

World Health Organization
ratios of SRS-based deaths to rescaled GBD2016 deaths were calculated from the SRS data for period 2002 (2001-2003) and 2011.5 (2010-2013). The scale factors were linearly interpolated for years 2003-2011 and extrapolated to year 2000 and 2016. They were then applied to the GBD2016 estimates to generate full time series for these causes consistent with the WHO analyses of the SRS data for 2001-2003 and 2010-2013. The remaining cause-specific estimates were based on information from WHO technical programs and UNAIDS on specific causes as described in Section 8.

In the analysis of the current GHE update for India, we continued to draw on the most up-to-date cause-specific estimates from WHO technical programs, UNAIDS and other Inter-agency groups where possible based on the inputs from the programmatic experts. However, as the current analysis extends to 2019, the crude interpolation and extrapolation method applied in previous GHE using data from only seven years to generate estimates for the entire period 2000-2019 would no longer be adequate for producing reliable estimates for other causes of deaths. Therefore, for other causes we made use of GBD2019 estimates which are based on more recent and additional SRS data as the primary source and supplement data sources for causes where the VA instrument is not most appropriate for ascertaining causes of death.4

8 Methods for specific causes with additional information

8.1 Tuberculosis

For countries without useable death registration data, total tuberculosis deaths were derived from latest published WHO estimates,30 together with more detailed unpublished age distributions based on the VR data and notifications data. For the countries with useable death registration data, the VR-based estimates were generally somewhat higher than the WHO estimates, as the GHE cause category for tuberculosis includes the ICD code for deaths due to late effects of tuberculosis.

8.2 HIV/AIDS and sexually transmitted diseases

(a) Countries with useable vital registration data

For countries with useable death registration data, estimates for HIV deaths were compared with UNAIDS/WHO estimates.7 In general, the VR-based estimates were used. For five countries the UNAIDS/WHO estimates were used: El Salvador, Nicaragua, Panama, Saint Lucia, Venezuela. For another five countries, an average of the UNAIDS-based and VR-based deaths was used: Armenia, Barbados, Paraguay, the Republic of Moldova, Sri Lanka.

(b) Other countries

For other countries, estimates were based on UNAIDS estimated HIV/AIDS mortality.7 The current UNAIDS data does not have estimates of HIV deaths for the following countries: Antigua and Barbuda, Grenada, Iraq, Kiribati, Micronesia, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Seychelles, Solomon Islands, Tonga and Vanuatu. HIV estimates for these countries were based on previous WHO GHE2016 estimates with projections.

8.3 Malaria

WHO publishes updates for malaria deaths (total, and under 5 years) by country for years from 2000 onwards in its annual World Malaria Report.31 The under 5 deaths are prepared in collaboration with the MCEE collaborative group and also reported in the MCEE-WHO child cause of death estimates.18,19 For Member States without useable death registration data, these WHO malaria mortality estimates are used in
GHE2019. The methods remain identical to those used for GHE2016 with updated data inputs, and are summarized in the following sections.

Under 5 deaths in countries with high quality VR data

For countries in which death reporting is estimated to capture > 50% of all deaths and a high proportion of malaria cases are parasitologically confirmed, reported malaria deaths are adjusted for completeness of death reporting. For countries in elimination programme phase, reported malaria deaths are adjusted for completeness of case reporting.

Under 5 deaths in countries outside the WHO African Region and low transmission countries in Africa

For countries (i) outside the African Region in which death reporting is estimated to capture ≤ 50% of all deaths or a high proportion of malaria cases are not parasitologically confirmed, or (ii) in the African Region where estimates of case incidence were derived from routine reporting systems and where malaria comprises less than 5% of all deaths in children under 5,\(^1\) case fatality rates are used to derive number of deaths from case estimates. A case fatality rate of 0.256% is applied to the estimated number of *P. falciparum* cases, being the average of case fatality rates reported in the literature\(^32–34\) and unpublished data from Indonesia, 2004-2009 (correspondence with Dr. Ric Price, Menzies School of Health Research). A case fatality rate of 0.0375% is applied to the estimated number of *P. vivax* cases, representing the mid-point of the range of reported case fatality rates.\(^35\) The number of cases reported by a Ministry of Health is adjusted to take into account (i) incompleteness in reporting systems (ii) patients seeking treatment in the private sector, self-medicating or not seeking treatment at all, and (iii) potential over-diagnosis through the lack of laboratory confirmation of cases.

Under 5 deaths in South Sudan and high transmission countries in the WHO African Region.

For countries in the African Region where malaria comprises 5% or more of all deaths in children under 5, malaria deaths were estimated using a multinomial logistic regression model fitted to available verbal autopsy data sets. This model is described in more detail elsewhere and draws on geospatial estimates of parasite prevalence rates produced by the Malaria Atlas Project at Oxford University in close collaboration with WHO.\(^18,19\)

Malaria deaths at ages 5 and over.

The estimated malaria mortality rate in children under 5 years for a country was used to determine malaria transmission intensity and the corresponding malaria-specific mortality rates in older age groups.\(^31\)

8.4 Measles

Estimates of measles deaths were prepared using a statistical model which firstly estimates measles cases by country and year using surveillance data and then makes explicit projections about dynamic transitions over time as well as overall patterns in incidence. Age-specific case fatality ratios are then applied for each country to estimate deaths.\(^36\) Measles deaths have been updated to take into account trends in case notifications and vaccine coverage up to and including the year 2019.\(^37\)

8.5 Cysticercosis, echinococcosis and food-borne trematodes

In 2007, the World Health Organization (WHO) established the Foodborne Disease Burden Epidemiology Reference Group (FERG) to estimate global and regional burdens of foodborne disease. Included among the parasitic foodborne diseases analysed were cysticercosis, echinococcus, and food-borne trematodosis. In
2015, the FERG published regional and global estimates of deaths and DALYs for these diseases for the year 2010 (45, 46). The GBD2019 time series estimates of deaths for these three diseases were scaled to match the underlying FERG estimates of deaths by country in 2010.

### 8.6 Cancers

Cause-specific estimates for cancer deaths in 2018 were derived from Globocan 2018.\(^3^8\) For countries without useable death registration data, site-specific deaths were projected back to year 2000 and forward to 2019 using trend estimates from the GBD2019. For countries with useable death registration data, cancer deaths by site were estimated from the death registration data directly with the various adjustments and redistributions described in Section 4.

Kaposis sarcoma was excluded from the Globocan estimates as this is almost entirely a manifestation of HIV/AIDS, already included in the estimates for HIV/AIDS deaths.

### 8.7 Maternal causes of death

Country-specific estimates for maternal mortality were based on the most recent Interagency estimates for years 2000-2017.\(^1^7\) A multilevel regression model for the proportion of total female deaths in the age range 15-49 that were due to maternal causes (PM) was developed using available national-level data from surveys, censuses, surveillance systems and death registration data.

Because the WHO life tables, and hence the total female deaths in the maternal age range, have been revised, the interagency PM estimates have been applied to the new envelopes to estimate numbers of maternal deaths. This has resulted in changes in the estimates of maternal deaths for some countries although regional and global totals have changed little.

Note that the maternal mortality estimates include those HIV deaths occurring in pregnant women or within 42 days of end of pregnancy which were considered to be indirect maternal deaths rather than incidental. These HIV maternal deaths were subtracted from total HIV deaths as estimated by UNAIDS.

### 8.8 Alcohol use and drug use disorders

The injury codes for accidental poisoning by alcohol and by opioids are now used to code acute intoxication deaths from alcohol and acute overdose deaths by opioids. These deaths have been remapped to alcohol use disorders and drug use disorders respectively (see Annex Table A). This mapping is complicated by the need to distribute the accidental poisoning category for “other and unspecified drugs, medicaments and biological substances” (X44) to the specific categories for drug use disorders (opioids, cocaine, amphetamines, cannabis and “other drugs”). Additionally, there is a category F19 in the mental health chapter for “multiple drug use and unspecified drug use disorders” which is used to code deaths in some countries and also must be redistributed appropriately.

GHE drug dependence deaths have been updated for all countries drawing on GBD2017 cause fractions. Additionally, estimates for the USA have been updated using US death registration data for 2016 (not available when GHE2016 was prepared) together with published analyses of drug-specific overdose deaths in the USA.\(^3^9\) Drug overdose and dependence deaths for Australia and Canada were also revised to take into account latest published statistics and death registration data.\(^4^0,^4^1\)
8.9 Road injuries

For the third WHO Global status report on road safety, updated estimates of road injury deaths were prepared for 182 Member States for the years 2000-2016. These estimates drew on death registration data and on reported road traffic deaths from official road traffic surveillance systems (collected in a WHO survey of Member States for the report).

Road injury deaths were projected forward to 2019 using recent trends in death registration data where available, or the trend for recent years to 2019 from the GBD2019.

8.10 Homicide

Updated estimates of homicide deaths for WHO Member States were published by WHO for years 2000-2012 in the Global status report on violence prevention 2014. These were projected forward to 2019 using recent trends in death registration data and GBD data where available.

8.11 Natural disasters

Estimated deaths for major natural disasters were obtained from estimates of GBD2019 which are based on information from the EM-DAT/CRED International Disaster Database. These data were used to supplement the VR data as described in the previous WHO Life Tables Technical Paper.

8.12 Conflict

Similar to natural disasters, we used GBD2019 data for conflict and terrorism which were primarily estimated using data from the Uppsala Conflict Data Program (UCDP), International Institute for Strategic Studies (IISS), Armed Conflict Location & Event Data Project (ACLED), Global Terrorism Database (GTD), supplemented by vital registration systems and other relevant data sources. Deaths were assigned for each event according to the source’s cause coding and any description from available notes. When the deaths due to a certain event are reported across multiple locations and estimates by side were not provided, deaths were split between the population from both locations.

9 Other causes of death for countries without useable data

The Institute for Health Metrics and Evaluation (IHME) has developed covariate based estimation models for a large number of single causes as inputs to its overall estimation of numbers of deaths by country, cause, age and sex. For this update of WHO Global Health Estimates for 2000-2019, we have similarly drawn on updated IHME single-cause analyses for the GBD2019 study, as described below.

To ensure that the results of all the single-cause models summed to the all-cause mortality estimate for each age-sex-country-year group, IHME applied a final step called CoDCorrect to rescale the cause-specific estimates. This was done using repeated random draws from the uncertainty distributions of each single cause and from the all-cause envelope, and proportionately rescaling each single cause estimate so they collectively summed to the envelope estimate. The overall effect is to “squeeze” or “expand” causes with wider uncertainty ranges more than those with narrower uncertainty ranges.

GBD2019 results, post-CoDCorrect, were used as inputs to estimate cause fractions by country, age, sex and year for causes of death at ages five years and above for which death registration data and/or WHO and UN Interagency analyses (described in Sections 4 to 8) were not available. For this set of causes, GBD 2019 country-level estimates for death rates at ages 5 and over for years 2000-2019 were used. For each year 2000 to 2019, cause fraction distributions were then computed for the set of causes excluding WHO/Interagency cause-specific estimates. For countries where these cause fractions were used, they were
applied to the country-level residual mortality envelopes by age and sex after the WHO/Interagency cause-specific estimates were subtracted from the WHO all-cause envelopes.

GBD results for priority causes such as HIV, TB, malaria, cancers, maternal mortality, child mortality differ to varying degrees from those of WHO and UN agency partners. In part, this reflects differences in modelling strategies, but also the inclusion by IHME of data from verbal autopsy (VA) studies which has been mapped to ICD categories using IHME-developed computer algorithms. As was done for GBD2019, we carried out a “GHECorrect” process to ensure that cause fractions across all causes added to 1 by age, sex, country and year, meaning that estimated numbers of deaths added across causes to the estimated total deaths by age, sex, country and year. This is described in more detail in the GHE2015 technical paper.1

The overall process of preparing the “prior” set of estimates for all countries for years 2000-2019 for the complete GHE cause list ensuring that inputs from WHO/UN sources and GBD2019 were consistent with the WHO all-cause envelopes is summarized in Figure 9.1. These “prior” estimates were used “as is” for causes of death at ages 5 and over for countries without death registration data meeting inclusion criteria, and also provided inputs to the preparation of, under 5 deaths and inputs for specific detailed cause breakdowns for certain cause groups for countries with death registration data.
Figure 9.1 Overview of the processes involved in the preparation of the GHE2019 “prior” estimates for all countries. Refer also to Figure 1.1 for further steps involved in the inclusion of this dataset in the final GHE2019 estimates.
10 Uncertainty of estimates

Many of the inputs to the GHE201 estimates have explicit uncertainty ranges. However, there are some specific cause inputs from WHO and UN sources which do not yet estimate quantitative uncertainty ranges. Given the challenges associated with calculating coherent quantitative uncertainty intervals with the available input data, guidance to users on the quality of underlying death registration data is available together with country estimates, using methods described below (section 10.1). In addition, quantitative uncertainty ranges are available as part of the comprehensive GHE2019 estimates dataset to be made available on the WHO website. Methods for these uncertainty ranges, as well as an overview of the quality of the uncertainty analysis, were described in the previous Technical Paper\(^2\) and are based on quantitative 95% uncertainty rates for cause-specific WHO/UN estimates together with 95% uncertainty ranges for other causes based on the broad variations of uncertainty in the GBD2019 estimates across cause categories and countries, with the latter grouped by data sources and methods.

These uncertainty intervals do not include all sources of uncertainty, and may not fully reflect uncertainty arising from differences in WHO/UN and IHME approaches to estimation for specific causes or countries. However, they do provide some minimal guidance to avoid over-interpretation of differences in death rates across causes or countries. In particular, care should be taken not to over-interpret detailed rankings of deaths by cause or country.

10.1 Guidance on underlying data quality

General guidance on the level of evidence available for death estimates is based on the quality of death registration data available in the WHO Mortality Database. Countries are classified into five levels, with descending quality of death registration data, as described in Table 10.1. Classification is based on three characteristics:

1. whether the data are reported by ICD code or with a summarized cause list,
2. the number of recent years of data available in the WHO mortality database, and
3. the average usability of the available data in the period 2008-present.

Usability is calculated as the product of the proportion of deaths assigned to a set of ill-defined cause of death codes\(^2\) and 100 less the percentage completeness. Because it is not possible to obtain the full number of deaths assigned to ill-defined causes of death when countries report death registration data using a summarized cause list, a more stringent set of usability cutoffs were defined for these countries.

---

\(^2\) ICD10 codes A40-A41, C76, C80, C97, D65, E86, I10, I26.9, I46, I47.2, I49.0, I50, I51.4-I51.6, I51.9, I70.9, I99, J81, J96, K72, N17-N19, P28.5, Y10-Y34, Y87.2
Table 10.1 Criteria for classification of countries by quality of death registration data

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>Color</th>
<th>Number of years of data reported to WHO since 2008</th>
<th>Average usability for years 2008-latest (countries reporting data to WHO by ICD code)</th>
<th>Average usability for years 2008-latest (countries reporting data to WHO by a shortlist)</th>
</tr>
</thead>
<tbody>
<tr>
<td>high</td>
<td>green</td>
<td>at least 5 years</td>
<td>usability &gt;= 80%</td>
<td>n/a</td>
</tr>
<tr>
<td>medium</td>
<td>light yellow</td>
<td>at least 5 years</td>
<td>usability &gt;= 60%</td>
<td>usability &gt;= 80%</td>
</tr>
<tr>
<td>low</td>
<td>dark yellow</td>
<td>at least 1 year</td>
<td>usability &gt;= 40%</td>
<td>usability &gt;= 60%</td>
</tr>
<tr>
<td>very low</td>
<td>pink</td>
<td>no minimum</td>
<td>does not qualify for any other category (usability &lt; 40%)</td>
<td>does not qualify for any other category (usability &lt; 60%)</td>
</tr>
</tbody>
</table>

The following guidance to users is provided together with the country data download:

- Multiple years of national death registration data with high completeness and quality of cause-of-death assignment are available. Estimates for these countries may be compared and time series may be used for priority setting and policy evaluation.

- Multiple years of death registration data are available. Data have low completeness and/or issues with cause-of-death assignment which likely affect estimated deaths by cause and time trends. Estimates may be used for priority setting. Use estimates for programme evaluation with caution, as improvements in the vital registration system may affect the estimated trends in cause-specific mortality. Comparisons among countries should be interpreted with caution. Light yellow denotes moderate quality issues and dark yellow denotes severe quality issues.

- Death registration data are unavailable or unusable due to quality issues. Estimates of mortality by cause should be interpreted with caution. Estimates may be used for priority setting, however, they are not likely to be informative for policy evaluation or comparisons among countries.
11 Conclusions

GHE2019 presents results for 183 WHO Member States, encompassing all those with a population of 90,000 or greater in 2019. The GHE2019 estimates of causes of death by country, region and world for years 2000-2019 confirm and expand previous WHO analyses of global health trends and improvements. In particular, these GHE2019 estimates of trends and levels of mortality by cause will contribute to WHO and UN monitoring and reporting of the health SDG goal and targets.

WHO’s adoption of health estimates is affected by a number of factors, including a country consultation process for country-level health estimates, existing multi-agency and expert group collaborative mechanisms, and compliance with standards around reporting data and methods. More detailed information on quality of data sources and methods, as well as estimated uncertainty intervals, is provided in in this document and in other referenced sources. As required by the GATHER guidelines (5), documentation of data inputs, methods, and results, including uncertainty, has improved (Annex C provides the location of each GATHER reporting item).

The type and complexity of models used for global health estimates varies widely by research/institutional group and health estimate. More complex models are necessary to generate more accurate uncertainty intervals. As expected, these require greater researcher expertise and time and computational resources to run. Where data are available and of high quality, estimates from different institutions are generally in agreement. Discrepancies are more likely to arise for countries where data are poor and for conditions where data are sparse and potentially biased. This is best addressed through improving the primary data.

Country health information systems, including vital registration, need to be strengthened as a matter of priority, in order to provide a more solid empirical basis for monitoring health situation and trends. Such data are also crucial for Member States’ monitoring of national and sub-national trends in order to respond to the changing needs of their populations.

To improve monitoring of mortality, morbidity and risk factors health information systems should focus on strengthening:

- Death registration through civil registration and vital statistics systems (CRVS), local health and demographic studies and other sources;
- Cause of death data collection through vital registration and verbal autopsy in communities;
- Regular household health surveys that include biological and clinical data collection; and
- Complete facility recording and reporting with regular quality control.

11.1 Reasons for changes in GHE estimates in this revision

As with previous revisions of WHO GHE and specific-cause time series estimates, GHE2019 provides an update for the entire time series from 2000 to 2019 incorporating data sources and specific WHO/interagency and IHME estimates released since GHE2019. This time series supercedes previous GHE time series, and differences between revision series should not be interpreted as time trends.

Major causes of significant changes in estimates or trends for individual countries or for specific causes at country, regional or global level include the following:

- The revision of WHO life table time series for Member States. This resulted in changes in the estimates of overall mortality rates for a number of countries, thus also affecting the estimates of causes of death.
- The revision of methods for assessing the completeness of VR data. The adoption of a more advanced death distribution method has led to changes in the completeness estimates for VR data in some
• Revision of maternal mortality estimates to take account of revisions to all-cause mortality envelopes in the reproductive age range 15-49 years.
• Use of the recently published GBD 2019 study for GHE2019. There were substantial changes in GBD 2019 estimates for some causes and countries compared to the previous GBD 2016 estimates used for GHE2016.
• Improvements to the GHECorrect process (Section 9.2) used to ensure that cause-specific estimates summed to WHO all-cause mortality estimates derived from WHO life tables.
• Improvements in the availability of death registration data for many countries.
• Use of GBD2019 prior estimates instead of death registration data for four countries which provide data to WHO only using a shortlist of ICD code groups (Belarus, Kazakhstan, Russia, and Ukraine).

11.2 Limitations of GHE estimates

Here we highlight some broad cross-cutting limitations to the GHE mortality and cause of death analysis. Comparable information about death numbers and rates by age, sex, cause, year, and country provides important information for priority setting discussions and for monitoring and evaluating progress towards global health goals. Major limitations and challenges are summarized below.

• All-cause mortality estimates in countries without well-functioning death registration systems relies heavily on census and survey data sources (particularly sibling survival data) and the use of model life tables. There is not yet consensus on the methods for analyzing sibling survival data or assessing levels of under-reporting of deaths in surveys or censuses.

• Demographic methods for the assessment of completeness of death registration all involve strong assumptions or information about migration and are prone to error resulting from age mis-statement in registration or census data, and to differential completeness of successive censuses.

• Estimation of HIV mortality relies on imputation of deaths from seroprevalence data using limited information on survival curves for HIV-positive persons not receiving or receiving anti-retroviral treatment (ART), and on the coverage of ART in populations. This results in large uncertainty for countries with high prevalence of HIV, as disease progression rates may well vary across countries.

• Although death registration data is generally the best form of information available on causes of death, it has considerable limitations, even in well-functioning systems with medical certification of cause of death. The so-called garbage codes represent a substantial proportion of deaths in some countries, and methods for re-assigning these deaths to valid causes are highly uncertain and generally are not based on empirical data. The assignment of underlying cause of death is limited by the information provided on the death certificate and quite sensitive to the order in which diagnoses are written. For most causes of death, variability (due to differences in physician practice when certifying a death) in assignment of valid causes of underlying death has not been addressed to date. Additionally, some diseases and injuries have specific problems associated with difficulty in making causal judgments of underlying cause (eg. diabetes and heart disease, or Alzheimer’s disease and heart disease, drug or alcohol overdose). Finally, HIV and other stigmatized causes of death, such as suicide, are routinely miscoded; the miscoding rate varies by setting.

• For many countries without functioning death registration systems, particularly in Africa, there is strong reliance on verbal autopsy studies, most of which are not nationally representative samples. Until recently there has been considerable variation in verbal autopsy instruments, and in analysis and cause assignment methods. Validation studies are challenging, and difficult to generalize to other settings.
• The WHO GHE estimates bring together single cause analyses from a number of WHO departments, interagency collaborations, and other sources, together with estimates drawn from the GBD 2019 study. These estimates are updated on differing time tables, and using different methods and assumptions in some cases, and it is more difficult to ensure consistency across causes, than is the case for large comprehensive estimates such as GBD 2019 prepared by a single study group. In addition, separate preparation of estimates of total mortality and cause-specific mortality can lead to incompatible cause-specific and total mortality estimates. In some cases, WHO/UN estimates are prepared only for all-age deaths, and age patterns imputed from available sometimes limited evidence.

• Estimates of deaths associated with mortality shocks (mainly conflict and disasters, but also some epidemics) are highly uncertain, and age patterns are generally imputed from limited data for other shocks. Additionally, in countries without functioning death registration systems or high quality censuses, it is very difficult to take account of, and to estimate, indirect mortality associated with mortality shocks, with increases in non-injury mortality rates associated with disruption to health and other social systems.

• While the uncertainty estimates discussed in Section 10 provide some guidance on the limitations of interpretation of the results, it should be kept in mind that these estimates reflect a subset of sources of uncertainty, and true uncertainty is higher.
References


Annex Table A  GHE cause categories and ICD-10 codes

<table>
<thead>
<tr>
<th>GHE code</th>
<th>GHE cause name</th>
<th>ICD-10 codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>I. Communicable, maternal, perinatal and nutritional conditions*</td>
<td>A00-B99, D50-D53, D64.9, E00-E02, E40-E46, E50-E64, G00-G04, G14, H65-H66, J00-J22, N70-N73, O00-O99, P00-P96, U04</td>
</tr>
<tr>
<td>20</td>
<td>A. Infectious and parasitic diseases</td>
<td>A00-B99, G00-G04, G14, N70-N73, P37.3, P37.4</td>
</tr>
<tr>
<td>30</td>
<td>1. Tuberculosis</td>
<td>A15-A19, B90</td>
</tr>
<tr>
<td>40</td>
<td>2. STDs excluding HIV</td>
<td>A50-A64, N70-N73</td>
</tr>
<tr>
<td>50</td>
<td>a. Syphilis</td>
<td>A50-A53</td>
</tr>
<tr>
<td>60</td>
<td>b. Chlamydia</td>
<td>A55-A56</td>
</tr>
<tr>
<td>70</td>
<td>c. Gonorrhoea</td>
<td>A54</td>
</tr>
<tr>
<td>80</td>
<td>d. Trichomoniasis</td>
<td>A59</td>
</tr>
<tr>
<td>85</td>
<td>e. Genital herpes</td>
<td>A60</td>
</tr>
<tr>
<td>90</td>
<td>f. Other STDs</td>
<td>A57-A58, A63-A64, N70-N73</td>
</tr>
<tr>
<td>100</td>
<td>3. HIV/AIDS</td>
<td>B20-B24</td>
</tr>
<tr>
<td>101</td>
<td>a. HIV resulting in TB</td>
<td>B20.0</td>
</tr>
<tr>
<td>102</td>
<td>b. HIV resulting in other diseases</td>
<td>B20-B24 (minus B20.0)</td>
</tr>
<tr>
<td>110</td>
<td>4. Diarrhoeal diseasesa</td>
<td>A00, A01, A03, A04, A06-A09</td>
</tr>
<tr>
<td>120</td>
<td>5. Childhood-cluster diseases</td>
<td>A33-A37, B05</td>
</tr>
<tr>
<td>130</td>
<td>a. Whooping cough</td>
<td>A37</td>
</tr>
<tr>
<td>140</td>
<td>b. Diphtheria</td>
<td>A36</td>
</tr>
<tr>
<td>150</td>
<td>c. Measles</td>
<td>B05</td>
</tr>
<tr>
<td>160</td>
<td>d. Tetanus</td>
<td>A33-A35</td>
</tr>
<tr>
<td>170</td>
<td>6. Meningitisb</td>
<td>A39, G00, G03</td>
</tr>
<tr>
<td>180</td>
<td>7. Encephalitisb</td>
<td>A83-A86, B94.1, G04</td>
</tr>
<tr>
<td>185</td>
<td>8. Hepatitis</td>
<td>B15-B19 (minus B17.8)</td>
</tr>
<tr>
<td>186</td>
<td>a. Acute hepatitis A</td>
<td>B15</td>
</tr>
<tr>
<td>190</td>
<td>b. Acute hepatitis B</td>
<td>B16-B19 (minus B17.1, B17.2, B18.2, B18.8)</td>
</tr>
<tr>
<td>200</td>
<td>c. Acute hepatitis C</td>
<td>B17.1, B18.2</td>
</tr>
<tr>
<td>205</td>
<td>d. Acute hepatitis E</td>
<td>B17.2, B18.8</td>
</tr>
<tr>
<td>210</td>
<td>9. Parasitic and vector diseases</td>
<td>A71, A82, A90-A91, A95, B50-B57, B65, B67, B69, B73, B74.0-B74.2, P37.3-P37.4</td>
</tr>
<tr>
<td>220</td>
<td>a. Malaria</td>
<td>B50-B54, P37.3, P37.4</td>
</tr>
<tr>
<td>230</td>
<td>b. Trypanosomiasis</td>
<td>B56</td>
</tr>
<tr>
<td>240</td>
<td>c. Chagas disease</td>
<td>B57</td>
</tr>
<tr>
<td>250</td>
<td>d. Schistosomiasis</td>
<td>B65</td>
</tr>
<tr>
<td>260</td>
<td>e. Leishmaniasis</td>
<td>B55</td>
</tr>
<tr>
<td>270</td>
<td>f. Lymphatic filariasis</td>
<td>B74.0-B74.2</td>
</tr>
<tr>
<td>280</td>
<td>g. Onchocerciasis</td>
<td>B73</td>
</tr>
<tr>
<td>285</td>
<td>h. Cysticercosis</td>
<td>B69</td>
</tr>
<tr>
<td>295</td>
<td>i. Echinococcosis</td>
<td>B67</td>
</tr>
<tr>
<td>300</td>
<td>j. Dengue</td>
<td>A90-A91</td>
</tr>
<tr>
<td>310</td>
<td>k. Trachoma</td>
<td>A71</td>
</tr>
<tr>
<td>315</td>
<td>l. Yellow fever</td>
<td>A95</td>
</tr>
<tr>
<td>320</td>
<td>m. Rabies</td>
<td>A82</td>
</tr>
<tr>
<td>330</td>
<td>10. Intestinal nematode infections</td>
<td>B76-B81</td>
</tr>
<tr>
<td>340</td>
<td>a. Ascariasis</td>
<td>B77</td>
</tr>
<tr>
<td>GHE code</td>
<td>GHE cause name</td>
<td>ICD-10 codes</td>
</tr>
<tr>
<td>----------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>350</td>
<td>b. Trichuriasis</td>
<td>B79</td>
</tr>
<tr>
<td>360</td>
<td>c. Hookworm disease</td>
<td>B76</td>
</tr>
<tr>
<td>362</td>
<td>d. Food-bourne trematodes</td>
<td>B78, B80, B81</td>
</tr>
<tr>
<td>365</td>
<td>11. Leprosy</td>
<td>A30</td>
</tr>
<tr>
<td>370</td>
<td>12. Other infectious diseases</td>
<td>A02, A05, A20-A28, A31, A32, A38, A40-A49, A65-A70, A74-A79, A80-A81, A87-A89, A92-A99, B00-B04, B06-B09, B17.8, B25-B49, B58-B60, B64, B66, B68, B70-B72, B74.3-B74.9, B75, B82-B89, B91-B99 (minus B94.1), G14</td>
</tr>
<tr>
<td>380</td>
<td>B. Respiratory infectious diseases</td>
<td>H65-H66, J00-J22, P23, U04</td>
</tr>
<tr>
<td>390</td>
<td>1. Lower respiratory infections</td>
<td>J09-J22, P23, U04</td>
</tr>
<tr>
<td>400</td>
<td>2. Upper respiratory infections</td>
<td>J00-J06</td>
</tr>
<tr>
<td>410</td>
<td>3. Otitis media</td>
<td>H65-H66</td>
</tr>
<tr>
<td>420</td>
<td>C. Maternal conditions</td>
<td>O00-O99</td>
</tr>
<tr>
<td>490</td>
<td>D. Neonatal conditions</td>
<td>P00-P96 (minus P23, P37.3, P37.4)</td>
</tr>
<tr>
<td>500</td>
<td>1. Preterm birth complications</td>
<td>P05, P07, P22, P27-P28</td>
</tr>
<tr>
<td>510</td>
<td>2. Birth asphyxia and birth trauma</td>
<td>P03, P10-P15, P20-P21, P24-P26, P29</td>
</tr>
<tr>
<td>520</td>
<td>3. Neonatal sepsis and infections</td>
<td>P35-P39 (minus P37.3, P37.4)</td>
</tr>
<tr>
<td>530</td>
<td>4. Other neonatal conditions</td>
<td>P00-P02, P04, P08, P50-P59</td>
</tr>
<tr>
<td>540</td>
<td>E. Nutritional deficiencies</td>
<td>D50-D53, D64.9, E00-E02, E40-E46, E50-E64</td>
</tr>
<tr>
<td>550</td>
<td>1. Protein-energy malnutrition</td>
<td>E40-E46</td>
</tr>
<tr>
<td>560</td>
<td>2. Iodine deficiency</td>
<td>E00-E02</td>
</tr>
<tr>
<td>570</td>
<td>3. Vitamin A deficiency</td>
<td>E50</td>
</tr>
<tr>
<td>580</td>
<td>4. Iron-deficiency anaemia</td>
<td>D50, D64.9</td>
</tr>
<tr>
<td>590</td>
<td>5. Other nutritional deficiencies</td>
<td>D51-D53, E51-E64</td>
</tr>
<tr>
<td>600</td>
<td>II. Noncommunicable diseases</td>
<td>C00-C97, D00-D48, D55-D64 (minus D 64.9), D65-D89, E03-E07, E10-E34, E65-E88, F01-F99, G08-G98 (minus G14), H00-H61, H68-H93, I00-I99, J00-J98, K00-K92, L00-L98, M00-M99, N00-N64, N75-N98, Q00-Q99, X41-X42, X44, X45, R95</td>
</tr>
<tr>
<td>610</td>
<td>A. Malignant neoplasms</td>
<td>C00-C97</td>
</tr>
<tr>
<td>620</td>
<td>1. Mouth and oropharynx cancers</td>
<td>C00-C14</td>
</tr>
<tr>
<td>621</td>
<td>a. Lip and oral cavity</td>
<td>C00-C08</td>
</tr>
<tr>
<td>622</td>
<td>b. Nasopharynx</td>
<td>C11</td>
</tr>
<tr>
<td>623</td>
<td>c. Other pharynx</td>
<td>C09-C10, C12-C14</td>
</tr>
<tr>
<td>630</td>
<td>2. Oesophagus cancer</td>
<td>C15</td>
</tr>
<tr>
<td>640</td>
<td>3. Stomach cancer</td>
<td>C16</td>
</tr>
<tr>
<td>650</td>
<td>4. Colon and rectum cancers</td>
<td>C18-C21</td>
</tr>
<tr>
<td>660</td>
<td>5. Liver cancer</td>
<td>C22</td>
</tr>
<tr>
<td>670</td>
<td>6. Pancreas cancer</td>
<td>C25</td>
</tr>
<tr>
<td>680</td>
<td>7. Trachea, bronchus, lung cancers</td>
<td>C33-C34</td>
</tr>
<tr>
<td>690</td>
<td>8. Melanoma and other skin cancers</td>
<td>C43-C44</td>
</tr>
<tr>
<td>691</td>
<td>a. Malignant skin melanoma</td>
<td>C43</td>
</tr>
<tr>
<td>692</td>
<td>b. Non-melanoma skin cancer</td>
<td>C44</td>
</tr>
<tr>
<td>700</td>
<td>9. Breast cancer</td>
<td>C50</td>
</tr>
<tr>
<td>710</td>
<td>10. Cervix uteri cancer</td>
<td>C53</td>
</tr>
<tr>
<td>720</td>
<td>11. Corpus uteri cancer</td>
<td>C54</td>
</tr>
<tr>
<td>730</td>
<td>12. Ovary cancer</td>
<td>C56</td>
</tr>
<tr>
<td>740</td>
<td>13. Prostate cancer</td>
<td>C61</td>
</tr>
<tr>
<td>742</td>
<td>14. Testicular cancer</td>
<td>C62</td>
</tr>
<tr>
<td>745</td>
<td>15. Kidney, renal pelvis and ureter cancer</td>
<td>C64-C66</td>
</tr>
<tr>
<td>750</td>
<td>16. Bladder cancer</td>
<td>C67</td>
</tr>
<tr>
<td>751</td>
<td>17. Brain and nervous system cancers</td>
<td>C70-C72</td>
</tr>
<tr>
<td>GHE code</td>
<td>GHE cause name</td>
<td>ICD-10 codes</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>752</td>
<td>18. Gallbladder and biliary tract cancer</td>
<td>C23-C24</td>
</tr>
<tr>
<td>753</td>
<td>19. Larynx cancer</td>
<td>C32</td>
</tr>
<tr>
<td>754</td>
<td>20. Thyroid cancer</td>
<td>C73</td>
</tr>
<tr>
<td>755</td>
<td>21. Mesothelioma</td>
<td>C45</td>
</tr>
<tr>
<td>760</td>
<td>22. Lymphomas, multiple myeloma</td>
<td>C81-C90, C96</td>
</tr>
<tr>
<td>761</td>
<td>a. Hodgkin lymphoma</td>
<td>C81</td>
</tr>
<tr>
<td>762</td>
<td>b. Non-Hodgkin lymphoma</td>
<td>C82-C86, C96</td>
</tr>
<tr>
<td>763</td>
<td>c. Multiple myeloma</td>
<td>C88, C90</td>
</tr>
<tr>
<td>770</td>
<td>23. Leukaemia</td>
<td>C91-C95</td>
</tr>
<tr>
<td>780</td>
<td>24. Other malignant neoplasms</td>
<td>C17, C26-C31, C37-C41, C46-C49, C51, C52, C57-C60, C63, C68, C69, C74-C75, C77-C79</td>
</tr>
<tr>
<td>790</td>
<td><strong>B. Other neoplasms</strong></td>
<td></td>
</tr>
<tr>
<td>800</td>
<td><strong>C. Diabetes mellitus</strong></td>
<td>D00-D48</td>
</tr>
<tr>
<td>810</td>
<td><strong>D. Endocrine, blood, immune disorders</strong></td>
<td>D55-D64 (minus D64.9), D65-D89, E03-E07, E15-E34, E65-E88</td>
</tr>
<tr>
<td>811</td>
<td>1. Thalassaemias</td>
<td>D56</td>
</tr>
<tr>
<td>812</td>
<td>2. Sickle cell disorders and trait</td>
<td>D57</td>
</tr>
<tr>
<td>813</td>
<td>3. Other haemoglobinopathies and haemolytic anaemias</td>
<td>D55, D58-D59</td>
</tr>
<tr>
<td>814</td>
<td>4. Other endocrine, blood and immune disorders</td>
<td>D60-D64 (minus D64.9), D65-D89, E03-E07, E15-E34, E65-E88</td>
</tr>
<tr>
<td>820</td>
<td><strong>E. Mental and substance use disorders</strong></td>
<td>F04-F99, G72.1, Q86.0, X41-X42, X44, X45</td>
</tr>
<tr>
<td>830</td>
<td>1. Depressive disorders</td>
<td>F32-F33, F34.1</td>
</tr>
<tr>
<td>831</td>
<td>a. Major depressive disorder</td>
<td>F32-F33</td>
</tr>
<tr>
<td>832</td>
<td>b. Dysthymia</td>
<td>F34.1</td>
</tr>
<tr>
<td>840</td>
<td>2. Bipolar disorder</td>
<td>F30-F31</td>
</tr>
<tr>
<td>850</td>
<td>3. Schizophrenia</td>
<td>F20-F29</td>
</tr>
<tr>
<td>860</td>
<td>4. Alcohol use disorders</td>
<td>F10, G72.1, Q86.0, X45</td>
</tr>
<tr>
<td>870</td>
<td>5. Drug use disorders*</td>
<td>F11-F16, F18-F19*, X41-X42, X44*</td>
</tr>
<tr>
<td>871</td>
<td>a. Opioid use disorders</td>
<td>F11, X42</td>
</tr>
<tr>
<td>872</td>
<td>b. Cocaine use disorders</td>
<td>F14</td>
</tr>
<tr>
<td>873</td>
<td>c. Amphetamine use disorders</td>
<td>F15</td>
</tr>
<tr>
<td>874</td>
<td>d. Cannabis use disorders</td>
<td>F12</td>
</tr>
<tr>
<td>875</td>
<td>e. Other drug use disorders</td>
<td>F13, F16, F18, X41</td>
</tr>
<tr>
<td>880</td>
<td>6. Anxiety disorders</td>
<td>F40-F44</td>
</tr>
<tr>
<td>890</td>
<td>7. Eating disorders</td>
<td>F50</td>
</tr>
<tr>
<td>900</td>
<td>8. Autism and Asperger syndrome</td>
<td>F84</td>
</tr>
<tr>
<td>910</td>
<td>9. Childhood behavioural disorders</td>
<td>F90-F92</td>
</tr>
<tr>
<td>911</td>
<td>a. Attention deficit/hyperactivity syndrome</td>
<td>F90</td>
</tr>
<tr>
<td>912</td>
<td>b. Conduct disorder</td>
<td>F91-F92</td>
</tr>
<tr>
<td>920</td>
<td>10. Idiopathic intellectual disability</td>
<td>F70-F79</td>
</tr>
<tr>
<td>930</td>
<td>11. Other mental and behavioural disorders</td>
<td>F04-F09, F17, F34-F39 (minus F34.1), F45-F48, F51-F69, F80-F83, F88-F89, F93-F99</td>
</tr>
<tr>
<td>940</td>
<td><strong>F. Neurological conditions</strong></td>
<td>F01-F03, G06-G98 (minus G14, G72.1)</td>
</tr>
<tr>
<td>950</td>
<td>1. Alzheimer disease and other dementias</td>
<td>F01-F03, G30-G31</td>
</tr>
<tr>
<td>960</td>
<td>2. Parkinson disease</td>
<td>G20-G21</td>
</tr>
<tr>
<td>970</td>
<td>3. Epilepsy</td>
<td>G40-G41</td>
</tr>
<tr>
<td>980</td>
<td>4. Multiple sclerosis</td>
<td>G35</td>
</tr>
<tr>
<td>990</td>
<td>5. Migraine</td>
<td>G43</td>
</tr>
<tr>
<td>GHE code</td>
<td>GHE cause name</td>
<td>ICD-10 codes</td>
</tr>
<tr>
<td>----------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>1000</td>
<td>6. Non-migraine headache</td>
<td>G44</td>
</tr>
<tr>
<td>1010</td>
<td>7. Other neurological conditions</td>
<td>G06-G12, G23-G25, G36-G37, G45-G98 (minus G72.1)</td>
</tr>
<tr>
<td>1020</td>
<td>G. Sense organ diseases</td>
<td>H00-H61, H68-H93</td>
</tr>
<tr>
<td>1030</td>
<td>1. Glaucoma</td>
<td>H40</td>
</tr>
<tr>
<td>1040</td>
<td>2. Cataracts</td>
<td>H25-H26</td>
</tr>
<tr>
<td>1050</td>
<td>3. Uncorrected refractive errors</td>
<td>H49-H52</td>
</tr>
<tr>
<td>1060</td>
<td>4. Macular degeneration</td>
<td>H35.3</td>
</tr>
<tr>
<td>1070</td>
<td>5. Other vision loss</td>
<td>H30-H35 (minus H35.3), H53-H54</td>
</tr>
<tr>
<td>1080</td>
<td>6. Other hearing loss</td>
<td>H90-H91</td>
</tr>
<tr>
<td>1100</td>
<td>H. Cardiovascular diseases</td>
<td>I00-I99</td>
</tr>
<tr>
<td>1110</td>
<td>1. Rheumatic heart disease</td>
<td>I01-I09</td>
</tr>
<tr>
<td>1120</td>
<td>2. Hypertensive heart disease</td>
<td>I11-I15</td>
</tr>
<tr>
<td>1130</td>
<td>3. Ischaemic heart disease</td>
<td>I20-I25</td>
</tr>
<tr>
<td>1140</td>
<td>4. Stroke</td>
<td>I60-I69</td>
</tr>
<tr>
<td>1150</td>
<td>5. Cardiomyopathy, myocarditis, endocarditis</td>
<td>I30-I33, I38, I40, I42</td>
</tr>
<tr>
<td>1160</td>
<td>6. Other circulatory diseases</td>
<td>I00, I26-I28, I34-I37, I44-I51, I70-I99</td>
</tr>
<tr>
<td>1170</td>
<td>I. Respiratory diseases</td>
<td>J00-J98</td>
</tr>
<tr>
<td>1180</td>
<td>1. Chronic obstructive pulmonary disease</td>
<td>J04-J44</td>
</tr>
<tr>
<td>1190</td>
<td>2. Asthma</td>
<td>J45-J46</td>
</tr>
<tr>
<td>1200</td>
<td>3. Other respiratory diseases</td>
<td>J30-J39, J47-J98</td>
</tr>
<tr>
<td>1210</td>
<td>J. Digestive diseases</td>
<td>K00-K92</td>
</tr>
<tr>
<td>1220</td>
<td>1. Peptic ulcer disease</td>
<td>K25-K27</td>
</tr>
<tr>
<td>1230</td>
<td>2. Cirrhosis of the liver</td>
<td>K70, K74</td>
</tr>
<tr>
<td>1240</td>
<td>3. Appendicitis</td>
<td>K35-K37</td>
</tr>
<tr>
<td>1241</td>
<td>4. Gastritis and duodenitis</td>
<td>K29</td>
</tr>
<tr>
<td>1242</td>
<td>5. Paralytic ileus and intestinal obstruction</td>
<td>K56</td>
</tr>
<tr>
<td>1244</td>
<td>6. Inflammatory bowel disease</td>
<td>K50-K52, K58.0</td>
</tr>
<tr>
<td>1246</td>
<td>7. Gallbladder and biliary diseases</td>
<td>K80-K83</td>
</tr>
<tr>
<td>1248</td>
<td>8. Pancreatitis</td>
<td>K85-K86</td>
</tr>
<tr>
<td>1271</td>
<td>a. Acute glomerulonephritis</td>
<td>N00-N01</td>
</tr>
<tr>
<td>1273</td>
<td>c. Other chronic kidney disease</td>
<td>N02-N19</td>
</tr>
<tr>
<td>1280</td>
<td>2. Benign prostatic hyperplasia</td>
<td>N40</td>
</tr>
<tr>
<td>1290</td>
<td>3. Urolithiasis</td>
<td>N20-N23</td>
</tr>
<tr>
<td>1300</td>
<td>4. Other urinary diseases</td>
<td>N25-N39, N41-N45, N47-N51</td>
</tr>
<tr>
<td>1310</td>
<td>5. Infertility</td>
<td>N46, N97</td>
</tr>
<tr>
<td>1320</td>
<td>6. Gynecological diseases</td>
<td>N60-N64, N75-N76, N80-N96, N98</td>
</tr>
<tr>
<td>1330</td>
<td>L. Skin diseases</td>
<td>L00-L98</td>
</tr>
<tr>
<td>1340</td>
<td>M. Musculoskeletal diseases</td>
<td>M00-M99</td>
</tr>
<tr>
<td>1350</td>
<td>1. Rheumatoid arthritis</td>
<td>M05-M06</td>
</tr>
<tr>
<td>1360</td>
<td>2. Osteoarthritis</td>
<td>M15-M19</td>
</tr>
<tr>
<td>1370</td>
<td>3. Gout</td>
<td>M10</td>
</tr>
<tr>
<td>1380</td>
<td>4. Back and neck pain</td>
<td>M45-M48, M50-M54</td>
</tr>
<tr>
<td>GHE code</td>
<td>GHE cause name</td>
<td>ICD-10 codes</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>1390</td>
<td>5. Other musculoskeletal disorders</td>
<td>M00, M02, M08, M11-M13, M20-M43, M60-M99</td>
</tr>
<tr>
<td>1400</td>
<td>N. Congenital anomalies</td>
<td>Q00-Q09 (minus Q86.0)</td>
</tr>
<tr>
<td>1410</td>
<td>1. Neural tube defects</td>
<td>Q00, Q05</td>
</tr>
<tr>
<td>1420</td>
<td>2. Cleft lip and cleft palate</td>
<td>Q28-Q37</td>
</tr>
<tr>
<td>1430</td>
<td>3. Down syndrome</td>
<td>Q90</td>
</tr>
<tr>
<td>1440</td>
<td>4. Congenital heart anomalies¹</td>
<td>Q20-Q28</td>
</tr>
<tr>
<td>1450</td>
<td>5. Other chromosomal anomalies</td>
<td>Q91-Q99</td>
</tr>
<tr>
<td>1460</td>
<td>6. Other congenital anomalies</td>
<td>Q01-Q04, Q06-Q18, Q30-Q34, Q38-Q89 (excluding Q86.0)</td>
</tr>
<tr>
<td>1470</td>
<td>O. Oral conditions</td>
<td>K00-K14</td>
</tr>
<tr>
<td>1480</td>
<td>1. Dental caries</td>
<td>K02</td>
</tr>
<tr>
<td>1490</td>
<td>2. Periodontal disease</td>
<td>K05</td>
</tr>
<tr>
<td>1500</td>
<td>3. Edentulism</td>
<td>-</td>
</tr>
<tr>
<td>1502</td>
<td>4. Other oral disorders</td>
<td>K00, K01, K03, K04, K06-K14</td>
</tr>
<tr>
<td>1505</td>
<td>P. Sudden infant death syndrome</td>
<td>R95</td>
</tr>
<tr>
<td>1510</td>
<td>III. Injuries⁵</td>
<td>V01-Y89 (minus X41-X42, X44, X45)</td>
</tr>
<tr>
<td>1520</td>
<td>A. Unintentional injuries</td>
<td>V01-X40, X43, X46-59, Y40-Y86, Y88, Y89</td>
</tr>
<tr>
<td>1530</td>
<td>1. Road injury</td>
<td>V01-V04, V06, V09-V80, V87, V89, V99</td>
</tr>
<tr>
<td>1540</td>
<td>2. Poisonings</td>
<td>X40, X43, X46-X48, X49</td>
</tr>
<tr>
<td>1550</td>
<td>3. Falls</td>
<td>W00-W19</td>
</tr>
<tr>
<td>1560</td>
<td>4. Fire, heat and hot substances</td>
<td>X00-X19</td>
</tr>
<tr>
<td>1570</td>
<td>5. Drowning</td>
<td>W65-W74</td>
</tr>
<tr>
<td>1580</td>
<td>7. Natural disasters</td>
<td>X33-X39</td>
</tr>
<tr>
<td>1600</td>
<td>B. Intentional injuries</td>
<td>X60-Y09, Y35-Y36, Y870, Y871</td>
</tr>
<tr>
<td>1610</td>
<td>1. Self-harm</td>
<td>X60-X84, Y870</td>
</tr>
<tr>
<td>1620</td>
<td>2. Interpersonal violence</td>
<td>X85-Y09, Y871</td>
</tr>
<tr>
<td>1630</td>
<td>3. Collective violence and legal intervention</td>
<td>Y35-Y36</td>
</tr>
</tbody>
</table>

---, not available

¹ Deaths coded to “Symptoms, signs and ill-defined conditions” (R00-R94, R96-R99) are distributed proportionately to all causes within Group I and Group II.

² For deaths under age 5, refer to classification in Annex Tables B.

³ Cancer deaths coded to ICD categories for malignant neoplasms of other and unspecified sites including those whose point of origin cannot be determined, and secondary and unspecified neoplasms (C76, C80, C97) were redistributed pro-rata across malignant neoplasm categories within each age–sex group, so that the category “Other malignant neoplasms” includes only malignant neoplasms of other specified sites.

⁴ Deaths assigned to ICD code C55, cancer of the uterus, part unspecified, and distributed pro-rata to cervix uteri cancer and corpus uteri cancer.

⁵ Deaths coded to F19 (Multiple and other drug use) and X44 (Accidental poisoning by other and unspecified drugs and medicines) have been redistributed to the GHE drug categories as described in Section 8.

⁶ Deaths assigned to a number of so-called cardiovascular “garbage” codes are reassigned to other underlying causes of death. These include heart failure, ventricular dysrhythmias, generalized atherosclerosis and ill-defined descriptions and complications of heart disease. Relevant ICD-10 codes are I46, I47.2, I49.0, I50, I51.4, I51.5, I51.6, I51.9 and I70.9. These are reassigned mainly to ischemic heart disease, but also to cardiomyopathy, myocarditis, endocarditis, chronic obstructive pulmonary disease, congenital heart anomalies, as described in Section 4.

⁷ Deaths assigned to essential hypertension (I10) were redistributed to ischemic heart disease, stroke, and kidney diseases.
Injury deaths where the intent is not determined (Y10-Y34, Y87.2) are distributed proportionately to all causes below the group level for injuries.

For countries with 3-digit ICD10 data, for “Road injury” use: V01-V04, V06, V09-V80, V87, V89 and V99. For countries with 4-digit ICD10 data, for “Road injury” use:

V01.1-V01.9, V02.1-V02.9, V03.1-V03.9, V04.1-V04.9, V06.1-V06.9, V09.2, V09.3, V10.3-V10.9, V11.3-V11.9, V12.3-V12.9, V13.3-V13.9, V14.3-V14.9, V15.4-V15.9, V16.4-V16.9, V17.4-V17.9, V18.4-V18.9, V19.4-V19.9, V20.3-V20.9, V21.3-V21.9, V22.3-V22.9, V23.3-V23.9, V24.3-V24.9, V25.3-V25.9, V26.3-V26.9, V27.3-V27.9, V28.3-V28.9, V29.4-V29.9, V30.4-V30.9, V31.4-V31.9, V32.4-V32.9, V33.4-V33.9, V34.4-V34.9, V35.4-V35.9, V36.4-V36.9, V37.4-V37.9, V38.4-V38.9, V39.4-V39.9, V40.4-V40.9, V41.4-V41.9, V42.4-V42.9, V43.4-V43.9, V44.4-V44.9, V45.4-V45.9, V46.4-V46.9, V47.4-V47.9, V48.4-V48.9, V49.4-V49.9, V50.4-V50.9, V51.4-V51.9, V52.4-V52.9, V53.4-V53.9, V54.4-V54.9, V55.4-V55.9, V56.4-V56.9, V57.4-V57.9, V58.4-V58.9, V59.4-V59.9, V60.4-V60.9, V61.4-V61.9, V62.4-V62.9, V63.4-V63.9, V64.4-V64.9, V65.4-V65.9, V66.4-V66.9, V67.4-V67.9, V68.4-V68.9, V69.4-V69.9, V70.4-V70.9, V71.4-V71.9, V72.4-V72.9, V73.4-V73.9, V74.4-V74.9, V75.4-V75.9, V76.4-V76.9, V77.4-V77.9, V78.4-V78.9, V79.4-V79.9, V80.3-V80.5, V81.1, V82.1, V82.8-V82.9, V83.0-V83.3, V84.0-V84.3, V85.0-V85.3, V86.0-V86.3, V87.0-V87.9, V89.2-V89.3, V89.9, V99 and Y850.
### Annex Table B  Groupings of countries, areas and territories used for global and regional tabulations

#### B.1  Global

Afghanistan, Albania, Algeria, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia (Plurinational State of), Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China; Taiwan, China; Colombia, Comoros, Congo, Costa Rica, Côte d'Ivoire, Croatia, Cuba, Cyprus, Czechia, Democratic People's Republic of Korea, Democratic Republic of the Congo, Denmark, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Eswatini, Estonia, Ethiopia, Fiji, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, India, Indonesia, Iran (Islamic Republic of), Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Lesotho, Liberia, Libya, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Mauritania, Mauritius, Mexico, Micronesia (Federated States of), Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Norway, Oman, Pakistan, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Republic of Korea, Republic of Moldova, Republic of North Macedonia, Romania, Russian Federation, Rwanda, Saint Lucia, Saint Vincent and the Grenadines, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syrian Arab Republic, Tajikistan, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Uganda, Ukraine, United Arab Emirates, United Kingdom, United Republic of Tanzania, United States of America, Uruguay, Uzbekistan, Vanuatu, Venezuela (Bolivarian Republic of), Viet Nam, West Bank and Gaza Strip, Yemen, Zambia, Zimbabwe

#### B.2  WHO Region*

##### WHO African Region

Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, South Sudan, Togo, Uganda, United Republic of Tanzania, Zambia, Zimbabwe

##### WHO Region of the Americas

Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia (Plurinational State of), Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, United States of America, Uruguay, Venezuela (Bolivarian Republic of)

##### WHO South-East Asia Region

Bangladesh, Bhutan, Democratic People's Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste

##### WHO European Region

Albania, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Malta, Montenegro, Netherlands, Norway, Poland, Portugal, Republic of Moldova, Republic of North Macedonia, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine, United Kingdom, Uzbekistan
WHO Eastern Mediterranean Region
Afghanistan, Bahrain, Djibouti, Egypt, Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Qatar, Saudi Arabia, Somalia, Sudan, Syrian Arab Republic, Tunisia, United Arab Emirates, Yemen

WHO Western Pacific Region
Australia, Brunei Darussalam, Cambodia, China, Fiji, Japan, Kiribati, Lao People’s Democratic Republic, Malaysia, Marshall Islands, Micronesia (Federated States of), Mongolia, New Zealand, Papua New Guinea, Philippines, Republic of Korea, Samoa, Singapore, Solomon Islands, Tonga, Vanuatu, Viet Nam

* WHO Member States with a population of less than 90,000 population in 2019 were not included in the analysis; these include: Andorra, Cook Islands, Dominica, Marshall Islands, Monaco, Nauru, Niue, Palau, Saint Kitts and Nevis, San Marino, Tuvalu.
B.3  World Bank income grouping*

Low income
Afghanistan, Benin, Burkina Faso, Burundi, Central African Republic, Chad, Democratic People's Republic of Korea, Democratic Republic of the Congo, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Liberia, Madagascar, Malawi, Mali, Mozambique, Nepal, Niger, Rwanda, Sierra Leone, Somalia, South Sudan, Togo, Uganda, United Republic of Tanzania

Lower middle income
Angola, Armenia, Bangladesh, Bhutan, Bolivia (Plurinational State of), Cabo Verde, Cambodia, Cameroon, Comoros, Congo, Côte d'Ivoire, Djibouti, Egypt, El Salvador, Eswatini, Ghana, Guatemala, Honduras, India, Indonesia, Jordan, Kenya, Kiribati, Kyrgyzstan, Lao People's Democratic Republic, Lesotho, Mauritania, Micronesia (Federated States of), Mongolia, Morocco, Myanmar, Nicaragua, Nigeria, Pakistan, Papua New Guinea, Philippines, Republic of Moldova, Sao Tome and Principe, Senegal, Solomon Islands, Sudan, Syrian Arab Republic, Tajikistan, Timor-Leste, Tunisia, Ukraine, Uzbekistan, Vanuatu, Viet Nam, West Bank and Gaza Strip, Yemen, Zambia, Zimbabwe

Upper middle income
Albania, Algeria, Azerbaijan, Belarus, Belize, Bosnia and Herzegovina, Botswana, Brazil, Bulgaria, China, Colombia, Costa Rica, Croatia, Cuba, Dominican Republic, Ecuador, Equatorial Guinea, Fiji, Gabon, Georgia, Grenada, Guyana, Iran (Islamic Republic of), Iraq, Jamaica, Kazakhstan, Lebanon, Libya, Malaysia, Maldives, Mauritius, Mexico, Montenegro, Namibia, Panama, Paraguay, Peru, Republic of North Macedonia, Romania, Russian Federation, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Serbia, South Africa, Sri Lanka, Suriname, Thailand, Tonga, Turkey, Turkmenistan, Venezuela (Bolivarian Republic of)

High income
Antigua and Barbuda, Argentina, Australia, Austria, Bahamas, Bahrain, Barbados, Belgium, Brunei Darussalam, Canada, Chile, Taiwan, China; Cyprus, Czechia, Denmark, Estonia, Finland, France, Hungary, Germany, Greece, Iceland, Ireland, Israel, Italy, Japan, Kuwait, Latvia, Lithuania, Luxembourg, Malta, Netherlands, New Zealand, Norway, Oman, Poland, Portugal, Puerto Rico, Qatar, Republic of Korea, Saudi Arabia, Seychelles, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Trinidad and Tobago, United Arab Emirates, United Kingdom, United States of America, Uruguay

* This regional grouping classifies countries, areas and territories according to the World Bank analytical income of economies based on the 2019 Atlas gross national income per capita estimates (World Bank list of economies, June 2020).
## Annex Table C  GATHER checklist

<table>
<thead>
<tr>
<th>Item #</th>
<th>Checklist item</th>
<th>Location reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Objectives and funding</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made.</td>
<td>Sections 2-3</td>
</tr>
<tr>
<td>2</td>
<td>List the funding sources for the work.</td>
<td>Acknowledgments</td>
</tr>
<tr>
<td><strong>Data Inputs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Describe how the data were identified and how the data were accessed.</td>
<td>Section 4.1</td>
</tr>
<tr>
<td>4</td>
<td>Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions.</td>
<td>Section 4.2</td>
</tr>
<tr>
<td>5</td>
<td>Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant.</td>
<td>Table 4.1: data with “Excluded” in the notes column were not used</td>
</tr>
<tr>
<td>6</td>
<td>Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5).</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>For data inputs that contribute to the analysis but were not synthesized as part of the study:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Describe and give sources for any other data inputs.</td>
<td>Section 2</td>
</tr>
<tr>
<td></td>
<td>Population by age and sex</td>
<td>Section 2</td>
</tr>
<tr>
<td></td>
<td>Total number of deaths by age and sex</td>
<td>Section 2</td>
</tr>
<tr>
<td></td>
<td>China/India</td>
<td>Sections 6-7</td>
</tr>
<tr>
<td></td>
<td>Program estimates of cause of death</td>
<td>Section 8</td>
</tr>
<tr>
<td></td>
<td>GBD2015 estimates for causes of death</td>
<td>Section 9</td>
</tr>
<tr>
<td><strong>For all data inputs:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data.</td>
<td><a href="http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html">http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html</a></td>
</tr>
<tr>
<td><strong>Data analysis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Provide a conceptual overview of the data analysis method. A diagram may be helpful.</td>
<td>Section 1</td>
</tr>
<tr>
<td></td>
<td>Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s).</td>
<td>Sections 4-10</td>
</tr>
<tr>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>11</td>
<td>Describe how candidate models were evaluated and how the final model(s) were selected</td>
<td>N/A: statistical models were not used to synthesize data</td>
</tr>
<tr>
<td>12</td>
<td>Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis.</td>
<td>N/A: statistical models were not used to synthesize data</td>
</tr>
<tr>
<td>13</td>
<td>Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis.</td>
<td>Section 10</td>
</tr>
<tr>
<td>14</td>
<td>State how analytic or statistical source code used to generate estimates can be accessed.</td>
<td>Acknowledgments (available upon request from <a href="mailto:healthstat@who.int">healthstat@who.int</a>)</td>
</tr>
</tbody>
</table>

**Results and Discussion**

| 16 | Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals). | Section 10 |
| 17 | Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates. | Section 11, Annex Table D |
| 18 | Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates. | Section 11 |
Annex Table D  Methods used for estimation of mortality levels and causes of death, by country, 2000-2019

All-cause mortality method groups:
VR: Life tables based on death rates computed from vital registration data.
VR-adj: Life tables based on mortality estimates for adults (age 15+ years) informed by completeness-adjusted vital registration data and child mortality estimates for ages under 15 years from the UN-IGME, with.
Non-VR: Life tables based on child mortality estimates for ages under 15 years from the UN-IGME and adult mortality estimates based on model life tables

Child cause of death methods:
VR data  Death registration data from the WHO Mortality Database
Sample VR  Cause of death data from the China Maternal and Child Surveillance System (MCMSS)
VRMCM  Multi-cause models based on death registration data
VAMCM  Multi-cause models based on verbal autopsy data
IndiaVAVR  Multi-cause models based on India state-level verbal autopsy and death registration data

Cause of death (COD) methods for ages 5+
Useable VR  See Section 4.
GBD2019+WHO  WHO/UNAIDS estimates for HIV deaths and all-cause deaths, GBD2019 study estimates, and WHO and UN Interagency cause-specific estimates (see Section 8 above)

Completeness
Note: (a) Completeness estimated for death registration data with cause of death for ages 15+ from the WHO Mortality Database. This estimate may differ from the completeness assessed for total registered deaths used in the development of WHO life tables (9).
<table>
<thead>
<tr>
<th>Country</th>
<th>All-cause mortality method</th>
<th>Neonatal method</th>
<th>1-59 method</th>
<th>month</th>
<th>COD method for ages 5+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Albania</td>
<td></td>
<td>VRMCM</td>
<td>VRMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Algeria</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Angola</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Antigua and Barbuda</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Argentina</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Armenia</td>
<td>VR-adj</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Australia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Austria</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Bahamas</td>
<td>NON-VR</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Bahrain</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Barbados</td>
<td>NON-VR</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Belarus</td>
<td>VR-adj</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Belgium</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Belize</td>
<td>NON-VR</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Benin</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Bhutan</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Bolivia (Plurinational State of)</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>VR-adj</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Botswana</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Brazil</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td></td>
<td>Useable VR</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Burundi</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Cabo Verde</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Cambodia</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Cameroon</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td></td>
<td>GBD2019+WHO</td>
</tr>
<tr>
<td>Country</td>
<td>All-cause method</td>
<td>Neonatal method</td>
<td>1-59 month method</td>
<td>COD method for ages 5+</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Central African Republic</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Chad</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Chile</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>NON-VR</td>
<td>Sample VR</td>
<td>Sample VR</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Comoros</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Congo</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Costa Rica</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Cote d'Ivoire</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Croatia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Cuba</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Cyprus</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Czechia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Democratic People's Republic of Korea</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Djibouti</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Ecuador</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Egypt</td>
<td>VR-adj</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>El Salvador</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Equatorial Guinea</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Eritrea</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Ethiopia</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Fiji</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Gabon</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Gambia</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>All-cause method</td>
<td>Neonatal method</td>
<td>1-59 month method</td>
<td>COD method for ages 5+</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>Georgia</td>
<td>VR-adj</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Ghana</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Grenada</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Guatemala</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Guinea</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Guyana</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Haiti</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Honduras</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Hungary</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Iceland</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>India</td>
<td>NON-VR</td>
<td>IndiaVAVR</td>
<td>IndiaVAVR</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Iran (Islamic Republic of)</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Iraq</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Jamaica</td>
<td>NON-VR</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Jordan</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Kenya</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Kiribati</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Kuwait</td>
<td>NON-VR</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Lao People's Democratic Republic</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Latvia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Lebanon</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>All-cause method</td>
<td>Neonatal method</td>
<td>1-59 month method</td>
<td>COD method for ages 5+</td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>Lesotho</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Liberia</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Libya</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Lithuania</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Luxembourg</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Madagascar</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Malawi</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Malaysia</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Maldives</td>
<td>VR-adj</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Mali</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Malta</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Mauritania</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Mauritius</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Micronesia (Federated States of)</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Mongolia</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Montenegro</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Morocco</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Mozambique</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Myanmar</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Namibia</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Nepal</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Nicaragua</td>
<td>NON-VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Niger</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Nigeria</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>West Bank and Gaza Strip</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019</td>
<td></td>
</tr>
<tr>
<td>Oman</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Pakistan</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>All-cause method</td>
<td>Neonatal method</td>
<td>1-59 month method</td>
<td>COD method for ages 5+</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>Panama</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Paraguay</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Peru</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Philippines</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>VR-adj</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Qatar</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Republic of Korea</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Republic of Moldova</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Romania</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Russian Federation</td>
<td>VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Rwanda</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Saint Vincent and the Grenadines</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Samoa</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Sao Tome and Principe</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Senegal</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Serbia</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Seychelles</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Singapore</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Somalia</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>Non-VR</td>
<td>VR data</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>South Sudan</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>All-cause method</td>
<td>Neonatal method</td>
<td>1-59 month method</td>
<td>COD method for ages 5+</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Sudan</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Suriname</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Swaziland</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Syrian Arab Republic</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Taiwan, China</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Tajikistan</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>The former Yugoslav Republic of Macedonia</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Timor-Leste</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Togo</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Tonga</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Tunisia</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Turkey</td>
<td>NON-VR</td>
<td>VR data</td>
<td>VR data</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Turkmnenistan</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Uganda</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Ukraine</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>United Republic of Tanzania</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>United States of America</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Uruguay</td>
<td>VR</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>VR-adj</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Vanuatu</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Venezuela (Bolivarian Republic of)</td>
<td>VR-adj</td>
<td>VR data</td>
<td>VR data</td>
<td>Useable VR</td>
<td></td>
</tr>
<tr>
<td>Viet Nam</td>
<td>NON-VR</td>
<td>VRMCM</td>
<td>VRMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Yemen</td>
<td>NON-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Zambia</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>Non-VR</td>
<td>VAMCM</td>
<td>VAMCM</td>
<td>GBD2019+WHO</td>
<td></td>
</tr>
</tbody>
</table>
Annex Table E  First-level categories for analysis of child causes of death

<table>
<thead>
<tr>
<th>GBD cause name</th>
<th>ICD-10 code</th>
<th>ICD-9 code</th>
</tr>
</thead>
<tbody>
<tr>
<td>All causes</td>
<td>A00-Y89</td>
<td>001-999</td>
</tr>
<tr>
<td>I. Communicable, maternal, perinatal and nutritional conditions*</td>
<td>A00-B99, D50-D53, D64.9, E00-E02, E40-E64, G00-G09, H65-H66, J00-J22, J85, N30, N94, N390, N70-N73, O00-P96, U04</td>
<td>001-139, 243, 260-269, 279.5-279.6, 280, 281, 285.9, 320-326, 381-382, 460-466, 480-487, 513, 614-616, 630-676, 760-779</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>B20-B24</td>
<td>279.5-279.6, 042</td>
</tr>
<tr>
<td>Diarrhoeal diseases</td>
<td>A00-A09</td>
<td>001-009</td>
</tr>
<tr>
<td>Pertussis</td>
<td>A37</td>
<td>033</td>
</tr>
<tr>
<td>Tetanus</td>
<td>A33-A35</td>
<td>037, 771.3</td>
</tr>
<tr>
<td>Measles</td>
<td>B05</td>
<td>055</td>
</tr>
<tr>
<td>Meningitis/encephalitis</td>
<td>A20.3, A32.1, A39.1, G00-G09</td>
<td>036, 320, 322-326</td>
</tr>
<tr>
<td>Malaria</td>
<td>B50-B54, P37.3, P37.4</td>
<td>084</td>
</tr>
<tr>
<td>Acute respiratory infections</td>
<td>H65-H66, J00-J22, J85, P23, U04</td>
<td>460-466, 480-487, 381-382, 513, 770.0</td>
</tr>
<tr>
<td>Prematurity</td>
<td>P01.0, P01.1, P07, P22, P25-P28, P52, P61.2, P77</td>
<td>761.0-761.1, 765, 769, 770.2-770.9, 772.1, 774.2, 776.6, 777.5-777.6,</td>
</tr>
<tr>
<td>Birth asphyxia &amp; birth trauma⁸</td>
<td>P01.7-P02.1, P02.4-P02.6, P03, P10-P15, P20-P21, P24, P50, P90-P91</td>
<td>761.7-762.1, 762.4-762.6, 763, 767-768, 770.1, 772.2, 779.0-779.2</td>
</tr>
<tr>
<td>Sepsis and other infectious conditions of the newborn</td>
<td>P35-P39 (exclude P37.3, P37.4)</td>
<td>771.0-771.2, 771.4-771.8</td>
</tr>
<tr>
<td>Other Group I</td>
<td>Remainder</td>
<td>Remainder</td>
</tr>
<tr>
<td>II. Noncommunicable diseases*</td>
<td>C00-C97, D00-D48, D55-D64 (exclude D64.9), D65-D89, E03-E34, E65-E88, F01-F99, G10-G98, H00-H61, H68-H93, I00-I99, J00-J84, J86-J98, K00-K92, L00-L98, M00-M99, N00-N28, N31-N32, N35-N64 (exclude N39.0), N75-N98, Q00-Q99</td>
<td>140-242, 244-259, 270-279, 282-285, 286-319, 330-380, 383-459, 470-478, 490-512, 514-611, 617-629, 680-759 (exclude 279.5-279.6, 285.9)</td>
</tr>
<tr>
<td>Congenital anomalies</td>
<td>Q00-Q99</td>
<td>740-759</td>
</tr>
<tr>
<td>Other Group II</td>
<td>Remainder</td>
<td>Remainder</td>
</tr>
<tr>
<td>III. Injuries</td>
<td>V01-Y89</td>
<td>E800-E99</td>
</tr>
</tbody>
</table>

* Deaths coded to “Symptoms, signs and ill-defined conditions” (780-799 in ICD-9 and R00-R99 in ICD-10) are distributed proportionately to all for neonatal deaths, but exclusively to Group I and Group II for the postneonatal deaths.

⁸ Also referred to as “intrapartum-related complications”